[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7094
1. Bell W, Warner JT, Evans WD, Webb DK, Mullen RH, Gregory JW: Perception of effort at low and moderate intensity exercise in survivors of childhood acute lymphoblastic leukaemia. Ann Hum Biol; 2006 May-Jun;33(3):357-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perception of effort at low and moderate intensity exercise in survivors of childhood acute lymphoblastic leukaemia.
  • OBJECTIVE: The study examined the degree to which male and female survivors of acute lymphoblastic leukaemia (ALL) perceive effort at low and moderate intensity exercise in association with related physiological variables.
  • [MeSH-major] Physical Exertion / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092872.001).
  • [ISSN] 0301-4460
  • [Journal-full-title] Annals of human biology
  • [ISO-abbreviation] Ann. Hum. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Wang SD, Yuan L, Jiang Y, Li XQ, Wang XZ: [Myocardial protective effect of Shenfu injection in patients undergoing valve replacement]. Zhonghua Yi Xue Za Zhi; 2007 Sep 4;87(33):2316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myocardial protective effect of Shenfu injection in patients undergoing valve replacement].
  • OBJECTIVE: To investigate the myocardial protective effect of Shenfu injection in patients undergoing valve replacement.
  • METHODS: Forty patients undergoing valve replacement surgery under cardio-pulmonary bypass (CPB) were randomly divided into two equal groups: group C (control group, given with 4:1 blood containing cardioplegic liquid during the CPB) and group SF (Shenfu injection, receiving the blood containing cardioplegic liquid with 20 ml/L of Shenfu injection additionally).
  • Blood samples were withdrawn from the central vein before operation, 30 minutes after aorta declamping, and 4, 12, and 24 hours after CPB, to test the serum cardiac troponin I (cTnI), creatine phosphokinase (CK), and creatine phosphokinase isoenzyme (CK-MB).
  • RESULTS: The CK, CK-MB, and cTnI level were normal before operation and there were no significant differences in these indexes between the two groups.
  • 30 minutes after aorta declamping, the CK, CK-MB, and cTnI levels were higher than those before operation in both groups (P < 0.05, P < 0.
  • 01), and the higher levels remained to 24 hours after CPB.
  • 24 hours after CPB, the CK level of the group SF was significantly lower than that of the group C (P < 0.05), and 30 minutes after aorta declamping to 24 h after CPB, the CK-MB and cTnI levels were lower in the group SF compared with the group C (all P < 0. 05).
  • CONCLUSION: Shenfu injection decreases the level of CK, CK-MB and cTnI, and reduces the myocardial injury.
  • [MeSH-major] Cardiomyopathies / prevention & control. Drugs, Chinese Herbal / therapeutic use. Heart Valve Prosthesis Implantation / methods
  • [MeSH-minor] Adult. Aged. Cardioplegic Solutions / administration & dosage. Cardiopulmonary Bypass. Cardiotonic Agents / administration & dosage. Cardiotonic Agents / therapeutic use. Creatine Kinase / blood. Creatine Kinase, MB Form / blood. Female. Heart Arrest, Induced / methods. Humans. Male. Middle Aged. Troponin I / blood

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036292.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cardioplegic Solutions; 0 / Cardiotonic Agents; 0 / Drugs, Chinese Herbal; 0 / Shen-Fu; 0 / Troponin I; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, MB Form
  •  go-up   go-down


3. Bashashati A, Nouredin B, Ward RK, Lawrence P, Birch GE: Effect of eye-blinks on a self-paced brain interface design. Clin Neurophysiol; 2007 Jul;118(7):1639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of eye-blinks on a self-paced brain interface design.
  • OBJECTIVE: To test the performance of an EEG-based self-paced brain interface when data contaminated with eye-blink artefacts are included in the evaluation.
  • METHODS: Two different designs of a self-paced brain interface (the low frequency-asynchronous switch design, LF-ASD) are evaluated and compared using offline data from eight subjects.
  • The true positive rates of the two designs are compared for three cases: (a) data containing eye-blink artefacts are excluded from the input;.
  • (b) all data, including eye-blinks, are included as input but the output decisions are inactivated during eye-blink artefacts;.
  • (c) all the data, including eye-blinks, are included as input and the output decisions are reported in all times including during eye-blink artefacts.
  • RESULTS: The true positive rates of one design of the LF-ASD (LF-ASD-V5) for case (c) and of another design (LF-ASD-V4) for case (b) are 40.5% and 42.4%, respectively, for false positive rates of 1%.
  • CONCLUSIONS: The true positive rates of LF-ASD-V5 when eye-blinks are included in the analysis deteriorate slightly compared to when the output during eye-blink artefacts is inactivated in LF-ASD-V4.
  • SIGNIFICANCE: LF-ASD-V5 allows the device to be functional at all times and can handle artefacts better than LF-ASD-V4.
  • If a slight decrease in true positive rates is acceptable, no further devices are needed to record the electro-oculogram (EOG) for detecting eye-blinks.
  • [MeSH-major] Artifacts. Blinking / physiology. Brain / physiology. Electroencephalography / instrumentation
  • [MeSH-minor] Adult. Data Interpretation, Statistical. Electrooculography. False Positive Reactions. Female. Fingers / physiology. Humans. Male. Middle Aged. Movement / physiology. ROC Curve. Spinal Cord Injuries / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466588.001).
  • [ISSN] 1388-2457
  • [Journal-full-title] Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  • [ISO-abbreviation] Clin Neurophysiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


Advertisement
4. Nyári TA, Kajtár P, Bartyik K, Thurzó L, McNally R, Parker L: Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys. Pathol Oncol Res; 2008 Dec;14(4):423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys.
  • The aim of this study was to investigate seasonal trends in the incidence of acute lymphoblastic leukaemia (ALL) around the times of birth and diagnosis in children aged 0-4 years and also to examine gender specific effects.
  • We found no seasonal effect related to date of diagnosis.
  • Our study provides some evidence that male specific immune responses to infections around the time of birth could explain the male predominance in the incidence of ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Seasons

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 1999 Apr;53(4):235-8 [10396550.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):549-53 [10507784.001]
  • [Cites] Lancet. 1969 Oct 18;2(7625):826-7 [4186286.001]
  • [Cites] J Community Health. 1982 Spring;7(3):159-70 [7076880.001]
  • [Cites] Br J Cancer. 1997;75(11):1711-3 [9184193.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):406-12 [11161408.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):51-5 [12802809.001]
  • [Cites] J Epidemiol Community Health. 1997 Apr;51(2):151-9 [9196644.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):119-24 [9662261.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):338-44 [11979458.001]
  • [Cites] Pediatr Blood Cancer. 2006 Dec;47(7):944-8 [16421899.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):678 [9484831.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):651-6 [12008082.001]
  • [Cites] Int J Epidemiol. 1992 Apr;21(2):381-6 [1428496.001]
  • [Cites] Lancet. 1989 Feb 18;1(8634):378-9 [2563524.001]
  • [Cites] BMC Public Health. 2003 Mar 24;3:13 [12659651.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Oct;15(4):338-45 [11703681.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):812-7 [9514063.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] JAMA. 2001 Jan 10;285(2):168-9 [11176808.001]
  • [Cites] Orv Hetil. 2003 Sep 21;144(38):1869-71 [14596025.001]
  • (PMID = 18409021.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Baillargeon J, Langevin AM, Mullins J, Ferry RJ Jr, DeAngulo G, Thomas PJ, Estrada J, Pitney A, Pollock BH: Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2005 Dec;45(7):960-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia.
  • BACKGROUND: Transient hyperglycemia occurs commonly during the treatment for childhood acute lymphoblastic leukemia (ALL).
  • The purpose of this study was to examine the incidence of and risk factors for transient hyperglycemia during induction chemotherapy in Hispanic pediatric patients diagnosed with B-Precursor ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • [Cites] Am J Dis Child. 1971 May;121(5):406-9 [5283023.001]
  • [Cites] J Nutr. 1998 Apr;128(4):701-6 [9521631.001]
  • [Cites] Am J Clin Nutr. 1994 Feb;59(2):307-16 [8310979.001]
  • [Cites] Diabetes Care. 1991 Feb;14(2):102-8 [2060411.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Feb;72(2):277-82 [1991798.001]
  • [Cites] N Engl J Med. 1986 Jul 24;315(4):215-9 [3523245.001]
  • [Cites] Eur J Clin Pharmacol. 1984;26(3):357-62 [6376142.001]
  • [Cites] J Pediatr. 1981 Jul;99(1):46-50 [6454771.001]
  • [Cites] J Clin Endocrinol Metab. 1980 Jan;50(1):113-6 [7350174.001]
  • [Cites] J Clin Endocrinol Metab. 1969 Oct;29(10):1373-6 [5353665.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1179-85 [15022284.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1728-32 [12365956.001]
  • [Cites] J Diabetes Complications. 1996 Sep-Oct;10(5):243-5 [8887011.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4591-6 [10599724.001]
  • [Cites] Pediatrics. 2000 Mar;105(3 Pt 1):671-80 [10699131.001]
  • [Cites] Arch Pediatr Adolesc Med. 2000 Aug;154(8):837-40 [10922283.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):225-43 [12350366.001]
  • (PMID = 15700246.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK002876-03; United States / NIDDK NIH HHS / DK / K08 DK002876; United States / NCI NIH HHS / CA / CA11078; United States / NIDDK NIH HHS / DK / K08 DK002876-03
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS293487; NLM/ PMC3102306
  •  go-up   go-down


6. Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J, Xu C, Dong L, Zhou M: [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun;10(3):290-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
  • OBJECTIVE: To study the prognostic factors for events-free survival (EFS) in children with acute non-mature B-lymphoblastic leukemia.
  • METHODS: One hundred and sixty-one children with newly diagnosed acute non-mature B-lymphoblastic leukemia received the ALL-XH-99 protocol treatment.
  • Age, initial white blood cell count (WBC), prednisone response, early response to treatment, fusion genes (BCR/ABL or MLL/AF4) and MRD level were significantly related to the EFS (P<0.01).
  • CONCLUSIONS: WBC >or=50 x 10(9)/L, Cmu positive, BCR/ABL or MLL/AF4 positive and MRD positive have important prognostic values in childhood acute non-mature B-lymphoblastic leukemia.
  • [MeSH-major] Burkitt Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Genes, abl. Humans. Infant. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm, Residual. Oncogene Proteins, Fusion / genetics. Prognosis. Regression Analysis


7. Akoz AG, Yildirim N, Engin H, Dagdas S, Ozet G, Tekin IO, Ceran F: An unusual case of spontaneous acute tumor lysis syndrome associated with acute lymphoblastic leukemia: a case report and review of the literature. Acta Oncol; 2007;46(8):1190-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of spontaneous acute tumor lysis syndrome associated with acute lymphoblastic leukemia: a case report and review of the literature.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tumor Lysis Syndrome / diagnosis. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Echocardiography. Female. Humans

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851839.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Norway
  • [Number-of-references] 20
  •  go-up   go-down


8. Böhm J, Immonen A, Riikonen P, Vanninen R, Alafuzoff I: Case report: central neurocytoma with concomitant cerebral involvement by acute lymphatic leukemia. Hum Pathol; 2006 Apr;37(4):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: central neurocytoma with concomitant cerebral involvement by acute lymphatic leukemia.
  • Leukemic infiltrates are occasionally seen as a complication of acute lymphatic leukemia.
  • This report describes a 7-year-old boy who was treated because of diagnosed lymphatic leukemia with central nervous system involvement and concomitant neurocytic tumor located in the fourth ventricle.
  • [MeSH-major] Brain Neoplasms / pathology. Fourth Ventricle / pathology. Leukemic Infiltration / pathology. Neoplasms, Second Primary. Neurocytoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564926.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Park HH, Kim M, Lee BH, Lim J, Kim Y, Lee EJ, Min WS, Kang CS, Kim WI, Shim SI, Han K: Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci; 2006;36(1):7-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia.
  • The quantitative levels of intracellular cytokines IL-4, IL-10, and IFN-gamma (ie, the number of bound PE-conjugated antibody molecules/cell) of leukemic cells and bone marrow T cells (bmT cells) of acute leukemia patients were analyzed by flow cytometry.
  • The leukemic cell IL-4 level was highest in the monocytic AML group (1735 +/- 1056) and lowest in the dysplastic AML group (960 +/- 545).
  • The IFN-gamma level was highest in the acute promyelocytic leukemia (APL) group (495 +/- 159), and lowest in the ALL group (252 +/- 119).
  • The IL-10 level was not significantly different among the diagnosis groups.
  • The leukemic cell cytokine levels were lowest and bmT cell cytokine levels were highest in the dysplastic AML group.
  • The cytokine levels of bmT cells at the time of CR became normal and were not different among the diagnosis groups.
  • In summary, leukemic cell and bmT cell cytoplasmic expression profiles of IL-4, IL-10, and IFN-gamma are characteristic for each diagnostic group of acute leukemia patients and the profiles of bmT cells are normal at the time of CR.
  • [MeSH-major] Bone Marrow Cells / metabolism. Interferon-gamma / blood. Interleukin-10 / blood. Interleukin-4 / blood. Leukemia / metabolism. T-Lymphocytes / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Remission Induction

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501231.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


10. Moschovi M, Trimis G, Tsotra M, Chatzi F, Karamolegou K, Santou A, Tourkantoni N, Chrousos G: Efficacy and safety of linezolid in immunocompromised children with cancer. Pediatr Int; 2010 Oct;52(5):694-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary diagnosis was acute lymphoblastic leukemia (nine patients), brain tumor (three patients), multi-organ Langerhans cell histiocytosis (two patients), rhabdomyosarcoma, Burkitt's lymphoma and ovarian tumor (one patient each).

  • Hazardous Substances Data Bank. LINEZOLID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pediatrics International © 2010 Japan Pediatric Society.
  • (PMID = 20149126.001).
  • [ISSN] 1442-200X
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Infective Agents; 0 / Oxazolidinones; ISQ9I6J12J / Linezolid
  •  go-up   go-down


11. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS: Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol; 2009 Mar 17;7(3):e59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic Kras initiates leukemia in hematopoietic stem cells.
  • Activating KRAS and NRAS mutations are among the most common oncogenic lesions detected in human cancer, and occur in myeloproliferative disorders (MPDs) and leukemias.
  • MPD could be initiated by Kras(G12D) expression in a highly restricted population enriched for hematopoietic stem cells (HSCs), but not in common myeloid progenitors.
  • Kras(G12D) HSCs demonstrated a marked in vivo competitive advantage over wild-type cells.
  • Transplanted Kras(G12D) HSCs efficiently initiated acute T-lineage leukemia/lymphoma, which was associated with secondary Notch1 mutations in thymocytes.
  • [MeSH-major] Hematopoietic Stem Cells / pathology. Leukemia, Experimental / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins p21(ras) / metabolism
  • [MeSH-minor] Animals. Base Sequence. Cell Proliferation. Cell Transformation, Neoplastic. Hematopoietic Stem Cell Transplantation. Mice. Mice, Inbred C57BL. Molecular Sequence Data. Myeloproliferative Disorders / metabolism. Myeloproliferative Disorders / pathology. Stem Cells / metabolism. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Jun 15;111(12):5562-70 [18424665.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4243-50 [14982883.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] Genes Dev. 2004 Oct 1;18(19):2336-41 [15371326.001]
  • [Cites] Blood. 2002 Feb 1;99(3):840-9 [11806985.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2310-3 [10979983.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):e92 [15247325.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):587-96 [15607963.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):221-6 [16015321.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell Cycle. 2007 Mar 1;6(5):550-66 [17351342.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2043-56 [10068678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4683-7 [8643464.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):51-7 [15982344.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7114-9 [16103884.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4185-93 [11110690.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3181-94 [18677410.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3373-82 [18663146.001]
  • [Cites] BMC Dev Biol. 2001;1:4 [11299042.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1257-68 [12807718.001]
  • [Cites] Blood. 2001 Aug 1;98(3):627-35 [11468160.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):324-37 [18371366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14541-6 [11724967.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):579-85 [16261595.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2655-64 [8839860.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1069-72 [16038733.001]
  • [Cites] Blood. 2007 May 1;109(9):3945-52 [17192389.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Cell. 2007 Jun 1;129(5):865-77 [17540168.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8953-8 [17517660.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(22):8736-40 [2247442.001]
  • [Cites] J Cell Biol. 1993 Aug;122(4):897-902 [8349737.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4314-20 [8943868.001]
  • [Cites] Cell. 2004 Oct 29;119(3):431-43 [15507213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Nature. 1983 Aug 18-24;304(5927):596-602 [6308472.001]
  • [Cites] Blood. 1990 Sep 15;76(6):1214-9 [2205309.001]
  • [Cites] Cytometry. 2000 Feb 1;39(2):108-16 [10679728.001]
  • [Cites] Nat Med. 2004 Aug;10(8):849-57 [15273746.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1044:1-5 [15958691.001]
  • [Cites] Am J Hematol. 1984 Apr;16(3):277-86 [6711557.001]
  • [Cites] Nature. 2001 Jun 28;411(6841):1017-21 [11429595.001]
  • [Cites] Eur J Immunol. 1988 Sep;18(9):1343-50 [3262519.001]
  • [Cites] Curr Opin Cell Biol. 1999 Dec;11(6):732-6 [10600705.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Exp Med. 2005 Dec 5;202(11):1599-611 [16330818.001]
  • [Cites] J Exp Med. 1997 May 5;185(9):1549-56 [9151892.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:65-72 [16869739.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] J Clin Invest. 2001 Sep;108(5):709-15 [11544276.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):393-8 [9670051.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3029-35 [14701873.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):547-52 [15607959.001]
  • [Cites] Stem Cells. 1996 Nov;14(6):690-701 [8948026.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1380-7 [10942381.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):507-14 [12498719.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • (PMID = 19296721.001).
  • [ISSN] 1545-7885
  • [Journal-full-title] PLoS biology
  • [ISO-abbreviation] PLoS Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084221; United States / NCI NIH HHS / CA / R37 CA72614; United States / NCI NIH HHS / CA / R37 CA072614; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / K08 CA103868; United States / NCI NIH HHS / CA / U01 CA84221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2656550
  •  go-up   go-down


12. Baptista MJ, Rocha G, Clemente F, Azevedo LF, Tibboel D, Leite-Moreira AF, Guimarães H, Areias JC, Correia-Pinto J: N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. Neonatology; 2008;94(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants.
  • Plasmatic N-terminal-pro-B type natriuretic peptide (NT-proBNP) might be useful in diagnosis and management of PH in newborns, although its interest in CDH infants remains to be defined.
  • [MeSH-major] Heart / physiopathology. Hernia, Diaphragmatic / physiopathology. Hernias, Diaphragmatic, Congenital. Hypertension, Pulmonary / blood. Hypertension, Pulmonary / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18160811.001).
  • [ISSN] 1661-7819
  • [Journal-full-title] Neonatology
  • [ISO-abbreviation] Neonatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


13. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM: Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood; 2009 Jun 18;113(25):6330-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
  • Immunophenotypic classification of acute lymphoblastic leukemia (ALL) has well-recognized prognostic implications.
  • The significance of CD20 expression has been evaluated in childhood precursor B-lineage ALL with conflicting results.
  • We retrospectively analyzed the influence of CD20 expression on outcome in 253 adults with de novo precursor B-lineage ALL treated with either conventional (VAD/CVAD) or intensive (hyper-CVAD) frontline chemotherapy regimens in the pre-rituximab era.
  • In conclusion, CD20 expression in de novo adult precursor B-lineage ALL appears to be associated with a poor prognosis.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1270-81 [17283164.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:435-43 [18024662.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 2:S57-62 [18284717.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1561-70 [18316581.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3906-11 [12816862.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):994-1004 [2189958.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2091-7 [7662956.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3960-6 [9166833.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):364-9 [9708202.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3302-4 [16896151.001]
  • (PMID = 18703706.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / 5K12 CA88084-2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2943753
  •  go-up   go-down


14. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM: Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol; 2006 Aug 15;98(4):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.
  • The aim of this study was to determine the usefulness of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) as a marker of exercise performance in HC.
  • Plasma NT-pro-BNP was measured in 171 consecutive patients (mean age 46 +/- 18 years) who underwent echocardiography and cardiopulmonary exercise testing.
  • The mean log NT-pro-BNP was 2.79 +/- 0.5; log NT-pro-BNP levels were higher in women patients (p = 0.001) and patients with chest pain (p = 0.010), in New York Heart Association class > or = II (p = 0.009), with atrial fibrillation (p < 0.001), with systolic impairment (p = 0.025), and with LV outflow tract obstructions (p < 0.0001).
  • NT-pro-BNP levels were also correlated with maximal wall thickness (r = 0.335, p < 0.0001), left atrial size (r = 0.206, p = 0.007), and the mitral Doppler E/A ratio (r = 0.197, p = 0.012).
  • There were inverse correlations between percent VO2max and NT-pro-BNP (r = -0.352, p = 0.001), LV end-systolic cavity size (r = -0.182, p = 0.031), and left atrial size (r = -0.251, p = 0.003).
  • On multivariate analysis, only NT-pro-BNP was correlated with percent VO2max.
  • A NT-pro-BNP level of 316 ng/L had 78% sensitivity and 44% specificity (area under the curve 0.616) for predicting percent VO2max < 80%.
  • In conclusion, NT-pro-BNP levels correlate with peak oxygen consumption in HC and are more predictive of functional impairment than other conventional markers of disease severity.

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893708.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


15. Gruhn B, Taub JW, Ge Y, Beck JF, Zell R, Häfer R, Hermann FH, Debatin KM, Steinbach D: Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia; 2008 Sep;22(9):1692-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy.
  • Recent studies with very small numbers of patients showed that in some cases of childhood acute lymphoblastic leukemia (ALL), preleukemic cells are detectable on Guthrie cards that were used for newborn screening.
  • Positive screening cards were not associated with patient's age at diagnosis but were almost always found in patients with hyperdiploidy (10/11; 91%; P=0.04).
  • In conclusion, the majority of childhood B-precursor ALL arise prior to birth.
  • In the search for causes of childhood leukemia we should concentrate on prenatal factors as well as postnatal factors.
  • Our results suggest that autologous cord bloods could be a poor choice as the source of stem cells for transplantation in leukemia, which may contain preleukemic cells.
  • Pending the development of suitable methods, childhood leukemia is a potentially screenable disease.
  • [MeSH-major] Aneuploidy. Birth Weight. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Preleukemia / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains. Infant. Infant, Newborn. Male. Neonatal Screening. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / etiology. Retrospective Studies


16. Elmaagacli AH, Koldehoff M, Zakrzewski JL, Steckel NK, Ottinger H, Beelen DW: Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate. Br J Haematol; 2007 Jan;136(2):212-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the GFI1B expression in erythroleukaemia and megakaryocytic leukaemia, as well as in patients with other subtypes of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), myelodysplastic syndrome (MDS), severe aplastic anaemia (SAA), myelofibrosis with myeloid metaplasia (MMM) and in healthy volunteers.
  • GFI1B expression was increased at least threefold in patients with erythroleukaemia (P < 0.01 compared with controls) and megakaryocytic leukaemia (P < 0.05) as well as in their corresponding leukaemic cell lines HEL, K562, CMK and M-07e.
  • Silencing GFI1B by transfection with small interfering RNA (siRNA) markedly reduced the proliferation rate in the leukaemic cell lines HEL, K562 and NB4 (P < 0.01).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia / metabolism. Proto-Oncogene Proteins / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Anemia, Aplastic / metabolism. Antigens, CD34 / immunology. Apoptosis. Case-Control Studies. Cell Cycle. Cell Line, Tumor. Gene Expression. Genes, myc. Humans. Immunophenotyping. Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Megakaryoblastic, Acute / metabolism. RNA Interference. RNA, Messenger / analysis. RNA, Small Interfering / genetics. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transfection / methods. rho GTP-Binding Proteins / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156408.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / GFI1B protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Repressor Proteins; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


17. Palermo CM, Bennett CA, Winters AC, Hemenway CS: The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. Leuk Res; 2008 Apr;32(4):633-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells.
  • Despite ongoing success in the treatment of childhood acute lymphoblastic leukemia, patients harboring translocations involving the MLL gene at chromosome 11q23 remain resistant to treatment.
  • To improve outcomes, novel therapeutics designed to target the unusual biology of these leukemias need to be developed.
  • Previously, we identified an interaction between the two most common MLL fusion proteins, AF4 and AF9, and designed a synthetic peptide (PFWT) capable of disrupting this interaction.
  • PFWT induced cell death in leukemia cells expressing MLL-AF4 with little effect on the colony forming potential of hematopoietic progenitor cells, suggesting the AF4-AF9 complex is an important pharmacological target for leukemia therapy and PFWT is a promising chemotherapeutic prototype.
  • Cell death is characterized by rapid loss of plasma membrane integrity with maintenance of nuclear membrane integrity, and is independent of caspase activation, DNA fragmentation, and mitochondrial membrane depolarization.
  • Given the resistance of t(4;11) leukemias to conventional chemotherapeutic agents that induce apoptosis, further identification of the molecular events mediating this death process should uncover new avenues for therapeutic intervention.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurobiol Aging. 2000 May-Jun;21(3):383-421 [10858586.001]
  • [Cites] Cell Death Differ. 2005 Sep;12(9):1219-24 [16094402.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1833-49 [11021759.001]
  • [Cites] Mutat Res. 2000 Nov 20;455(1-2):111-27 [11113471.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):439-44 [11212227.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):613-21 [11583623.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):432-8 [11606597.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):153-66 [11950215.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Pharmacol Res. 2003 Apr;47(4):355-62 [12644394.001]
  • [Cites] Prostate. 2003 May 1;55(2):147-57 [12661040.001]
  • [Cites] Cell Death Differ. 2003 Oct;10(10):1204-12 [14502243.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7414-30 [14576849.001]
  • [Cites] Leukemia. 2004 Jan;18(1):92-102 [14603337.001]
  • [Cites] Leukemia. 2004 Feb;18(2):227-32 [14671638.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2299-307 [14645012.001]
  • [Cites] Genes Dev. 2004 May 1;18(9):965-74 [15132992.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1272-82 [15145826.001]
  • [Cites] Cell Death Differ. 2004 Aug;11(8):937-9 [15044964.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Aug;310(2):425-36 [15075382.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1364-72 [15269783.001]
  • [Cites] Pharmacol Rev. 1972 Dec;24(4):583-655 [4565956.001]
  • [Cites] Blood. 1987 Jul;70(1):192-9 [3496132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3671-5 [2023917.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4631-5 [8506309.001]
  • [Cites] Br J Haematol. 1997 Jul;98(1):157-69 [9233580.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1469-77 [9305600.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1205-13 [9358745.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1561-4 [9766500.001]
  • [Cites] Curr Biol. 1999 Sep 9;9(17):967-70 [10508592.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1605-12 [16034464.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2005 Nov;37(11):719-27 [16270150.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2296-303 [16208414.001]
  • [Cites] Exp Cell Res. 2006 Jan 1;312(1):27-39 [16288739.001]
  • [Cites] Infect Immun. 2007 Apr;75(4):1984-93 [17283090.001]
  • [Cites] Curr Opin Immunol. 2003 Oct;15(5):553-9 [14499264.001]
  • [Cites] Leukemia. 1999 Oct;13(10):1539-47 [10516755.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):1907-16 [15784530.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3155-62 [15867207.001]
  • [Cites] Trends Neurosci. 2000 Sep;23(9):410-1 [10941188.001]
  • (PMID = 17875318.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098459-03; United States / NCI NIH HHS / CA / CA098459-03; United States / NCI NIH HHS / CA / CA098459-03S1; United States / NCRR NIH HHS / RR / P20 RR020152; United States / NCI NIH HHS / CA / CA 098459; United States / NCI NIH HHS / CA / R01 CA098459-03S2; United States / NCI NIH HHS / CA / R01 CA098459; United States / NCRR NIH HHS / RR / P20 RR020152-037527; United States / NCI NIH HHS / CA / R01 CA098459-03S1; United States / NCRR NIH HHS / RR / RR 020152; United States / NCI NIH HHS / CA / F32 CA 119474; United States / NCI NIH HHS / CA / F32 CA119474; United States / NCRR NIH HHS / RR / RR020152-037527; United States / NCI NIH HHS / CA / CA098459-03S2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL-AF4 fusion protein, human; 0 / MLLT3 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Peptide Fragments; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Other-IDs] NLM/ NIHMS41852; NLM/ PMC2270790
  •  go-up   go-down


18. Fasano RE, Bergen DC: Intractable epilepsy in patients treated for childhood acute lymphocytic leukemia. Seizure; 2009 May;18(4):298-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intractable epilepsy in patients treated for childhood acute lymphocytic leukemia.
  • PURPOSE: In the 1970s and 80s, standard treatment for childhood acute lymphocytic leukemia (ALL) included both intrathecal methotrexate and whole-brain irradiation.
  • During acute treatment, seizures were not uncommon.
  • We describe five patients who were treated for acute lymphocytic leukemia as children, who later developed intractable epilepsy.
  • RESULTS: All of the patients were diagnosed with leukemia before age seven.
  • The first seizure occurred at a mean of 7.5 years after diagnosis.
  • CONCLUSIONS: Successful treatment for childhood leukemia may be followed by signs of late cerebral injury including intractable epilepsy.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Cranial Irradiation / adverse effects. Epilepsy / etiology. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041267.001).
  • [ISSN] 1059-1311
  • [Journal-full-title] Seizure
  • [ISO-abbreviation] Seizure
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM: Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Pediatr Blood Cancer; 2005 Apr;44(4):378-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment.
  • BACKGROUND: Children undergoing treatment for acute lymphoblastic leukemia (ALL) receive combination chemotherapy and many of the components are associated with free radical production.
  • PROCEDURE: Among 103 children newly diagnosed with ALL, plasma concentrations of antioxidants, total antioxidant capacity (ORAC), and DNA oxidized base 8-oxodeoxyguanosine (8-oxo-dG) were analyzed at baseline and 3 and 6 months after diagnosis.
  • RESULTS: Plasma vitamin A, antioxidants, 8-oxo-dG, and ORAC changed from diagnosis through the first 6 months of ALL therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antioxidants / metabolism. Deoxyguanosine / analogs & derivatives. Oxidative Stress. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622521.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


20. Roll JD, Reuther GW: CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res; 2010 Oct 1;70(19):7347-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
  • Expression of cytokine receptor-like factor 2 (CRLF2) has recently been shown to be upregulated as well as mutated in populations of B-progenitor acute lymphoblastic leukemia (B-ALL), including Down syndrome (DS-ALL) patients, lacking recurring chromosomal translocations.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 AACR.
  • [Cites] J Immunol. 1999 Dec 1;163(11):5971-7 [10570284.001]
  • [Cites] Blood. 2010 Jul 1;115(26):5312-21 [20139093.001]
  • [Cites] Nat Immunol. 2000 Jul;1(1):59-64 [10881176.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2584-92 [14993294.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Immunol. 1999 Jan 15;162(2):677-83 [9916685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18502-7 [18003935.001]
  • [Cites] J Biol Chem. 2008 Feb 29;283(9):5258-66 [18158285.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Cell Cycle. 2008 Mar 15;7(6):714-9 [18245948.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3716-21 [18559588.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] Br J Haematol. 2009 Jan;144(2):147-56 [19006567.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] Adv Immunol. 2009;101:1-25 [19231591.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):930-2 [19120350.001]
  • [Cites] J Biol Chem. 2009 Mar 13;284(11):6773-81 [19139102.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2688-98 [19641190.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1243-6 [19838194.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7 [20018760.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1006-17 [19965641.001]
  • [Cites] Mucosal Immunol. 2010 Mar;3(2):138-47 [20016474.001]
  • [Cites] Leukemia. 2010 Mar;24(3):642-5 [19907440.001]
  • [Cites] J Biol Chem. 2010 May 28;285(22):16651-63 [20363735.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 9;281(4):878-83 [11237741.001]
  • (PMID = 20807819.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA127250; United States / NCI NIH HHS / CA / R01CA127250
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRLF2 protein, human; 0 / Receptors, Cytokine; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ NIHMS224663; NLM/ PMC2948596
  •  go-up   go-down


21. Riva G, Luppi M, Potenza L, Morselli M, Ferrari A, Saviola A, Volzone F, Imovilli A, Merighi A, Maiorana A, Torelli G: Cytomegalovirus and Clostridium Difficile co-infection in severe ulcero-hemorrhagic colitis during induction chemotherapy for acute lymphoblastic leukemia. Haematologica; 2005 Jan;90(1):ECR01
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus and Clostridium Difficile co-infection in severe ulcero-hemorrhagic colitis during induction chemotherapy for acute lymphoblastic leukemia.
  • Here we describe the first case of a biopsy-proven Cytomegalovirus ulcero-hemorrhagic colitis, associated with Clostridium Difficile co-infection, occurring during standard induction chemotherapy for common B cell acute lymphoblastic leukemia.
  • [MeSH-major] Clostridium difficile. Colitis, Ulcerative / microbiology. Colitis, Ulcerative / virology. Cytomegalovirus Infections / pathology. Enterocolitis, Pseudomembranous / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


22. Gatedee J, Pakakassama S, Muangman S, Pongstaporn W: Glutathione S-transferase P1 genotypes, genetic susceptibility and outcome of therapy in thai childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev; 2007 Apr-Jun;8(2):294-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione S-transferase P1 genotypes, genetic susceptibility and outcome of therapy in thai childhood acute lymphoblastic leukemia.
  • Polymorphisms of GSTP1 at codon 105 residue forms GSTP1 active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old.
  • In addition, the association of genetic polymorphism of GSTP1 and genetic susceptibility of acute lymphoblastic leukemia (ALL) was also determined using Chi-square and Odds ratio.
  • PCR-RFLP was used to study genetic polymorphism of GSTP1 in 100 ALL patients and 100 healthy individuals.The results show that there is no statistically significant association between each genotypes and genetic susceptibility of acute lymphoblastic leukemia (ALL) (OR=0.92, P -value=0.886).
  • Moreover, there is no statistically significant association between each genotypes and demographic data of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Genetic Predisposition to Disease. Glutathione S-Transferase pi / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


23. Riz I, Lee HJ, Baxter KK, Behnam R, Hawley TS, Hawley RG: Transcriptional activation by TLX1/HOX11 involves Gro/TLE corepressors. Biochem Biophys Res Commun; 2009 Mar 6;380(2):361-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TLX1 is a homeodomain transcription factor involved in splenogenesis and neuron formation, and its aberrant expression gives rise to T-cell acute lymphoblastic leukemia.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1578-84 [11035023.001]
  • [Cites] Br J Haematol. 2009 Apr;145(1):140-3 [19133982.001]
  • [Cites] Biotechniques. 2001 May;30(5):1028-34 [11355338.001]
  • [Cites] Genes Dev. 2002 May 15;16(10):1220-33 [12023301.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4966-74 [12586625.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):171-8 [15013216.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34938-47 [15187083.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Dec;41(4):309-20 [15384172.001]
  • [Cites] Nature. 1994 Apr 21;368(6473):747-9 [7908720.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):337-45 [9000579.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3502-8 [9584190.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7030-7 [9819390.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Cell. 2004 Dec 17;119(6):815-29 [15607978.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5561-75 [15897879.001]
  • [Cites] EMBO J. 2006 Jan 25;25(2):357-66 [16407974.001]
  • [Cites] Leukemia. 2006 Feb;20(2):304-12 [16357834.001]
  • [Cites] Mol Cell. 2006 Jun 9;22(5):645-55 [16762837.001]
  • [Cites] Oncogene. 2007 Jun 14;26(28):4115-23 [17213805.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):20868-76 [17526489.001]
  • [Cites] Trends Cell Biol. 2007 Jul;17(7):353-61 [17643306.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Mar 14;367(3):707-13 [18073142.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3257-66 [18787211.001]
  • [Cites] Cell. 2001 Mar 23;104(6):861-73 [11290324.001]
  • (PMID = 19250647.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL065519-07; United States / NHLBI NIH HHS / HL / R01HL65519; United States / NHLBI NIH HHS / HL / R01 HL066305-05; United States / NHLBI NIH HHS / HL / R01 HL065519; United States / NHLBI NIH HHS / HL / R01 HL066305; United States / NHLBI NIH HHS / HL / HL065519-07; United States / NHLBI NIH HHS / HL / R01 HL066305-04; United States / NHLBI NIH HHS / HL / HL066305-05; United States / NHLBI NIH HHS / HL / R01 HL065519-06; United States / NHLBI NIH HHS / HL / HL065519-06; United States / NHLBI NIH HHS / HL / R01HL66305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASCL1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / FHL1 protein, human; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIM Domain Proteins; 0 / Muscle Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / TLE1 protein, human; 143275-75-6 / TLX1 protein, human; EC 1.2.1.3 / ALDH1A1 protein, human; EC 1.2.1.3 / Aldehyde Dehydrogenase
  • [Other-IDs] NLM/ NIHMS92186; NLM/ PMC2654413
  •  go-up   go-down


24. Khawaja MR, Allana SS, Akbarali AN, Adil SN, Khurshid M, Pervez S: Flow cytometric and demographic analysis of t cell acute lymphoblastic leukemia in Pakistani population. J Ayub Med Coll Abbottabad; 2005 Oct-Dec;17(4):3-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric and demographic analysis of t cell acute lymphoblastic leukemia in Pakistani population.
  • BACKGROUND: This study was carried out to analyze the proportion of T cell acute lymphoblastic leukemia (TALL) among all acute lymphoblastic leukemia (ALL) in Pakistani population and its correlation with the demographic features.
  • Accuracy of cell surface markers used in flow cytometric analysis of the leukemic cells was also determined.
  • METHODS: Data of 209 consecutive cases of acute lymphoblastic leukemia (ALL) presenting between July 1995 and July 2003 was analyzed.
  • However, due to some aberrant and cross reactivity displayed by each marker, we strongly recommend a panel approach including B and myeloid markers to ensure a correct diagnosis of TALL.
  • [MeSH-major] Flow Cytometry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. T-Lymphocytes / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Biomarkers. Demography. Female. Humans. Male. Pakistan / epidemiology. Prevalence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599024.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


25. Nahi H, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VLj, Linderholm M, Smedmyr B, Aström M, Hallböök H: An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica; 2008 Nov;93(11):1734-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.
  • In acute lymphoblastic leukemia, besides age and white cell count at diagnosis, the cytogenetic abnormalities t(9;22)/BCR-ABL and t(4;11)/MLL-AF4 are important prognostic markers and are often included in the treatment stratification of patients with adult acute lymphoblastic leukemia.
  • Deletions in 9p are seen in about 9% of cases of adult acute lymphoblastic leukemia, but their prognostic impact has been controversial.
  • Cytogenetic data from 381 patients diagnosed with B-precursor acute lymphoblastic leukemia were reviewed.
  • Our data suggest that chromosomal abnormalities involving 9p may have a significant negative impact on survival in adult B-precursor acute lymphoblastic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / mortality. Chromosomes, Human, Pair 9. Sequence Deletion

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728022.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


26. Yang HK, Yu HG: Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease. Korean J Ophthalmol; 2009 Dec;23(4):325-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease.
  • We describe a case of bilateral exudative retinal detachment associated with prodromal symptoms simulating the presentation of acute Vogt-Koyanagi-Harada disease that was eventually diagnosed as acute lymphoblastic leukemia.
  • A clinical diagnosis of incomplete type Vogt-Koyanagi-Harada disease was considered.
  • However, complete blood cell count showed a marked increase in the number of white blood cells and bone marrow examination revealed precursor B cell lymphoblastic leukemia.
  • Bilateral exudative retinal detachment associated with neurologic and auditory abnormalities may be a presenting sign of acute lymphoblastic leukemia.
  • Clinicians should be aware of the possibility of leukemia in such patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology. Uveomeningoencephalitic Syndrome / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fluorescein Angiography. Follow-Up Studies. Fundus Oculi. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kaohsiung J Med Sci. 2001 Mar;17(3):150-5 [11486647.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):691-9 [12447107.001]
  • [Cites] Leuk Res. 2003 Jun;27(6):557-9 [12648516.001]
  • [Cites] Am J Ophthalmol. 1979 May;87(5):698-702 [443342.001]
  • [Cites] Ann Ophthalmol. 1979 Dec;11(12):1867-72 [299244.001]
  • [Cites] Am J Ophthalmol. 1987 Oct 15;104(4):364-72 [3661646.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • [Cites] Am J Ophthalmol. 1990 Apr 15;109(4):436-44 [2330946.001]
  • [Cites] Am J Ophthalmol. 1996 Jul;122(1):58-66 [8659599.001]
  • [Cites] Surv Ophthalmol. 1964 Oct;9:467-73 [14199728.001]
  • [Cites] Eur J Ophthalmol. 2005 Mar-Apr;15(2):284-6 [15812775.001]
  • [Cites] Retina. 2006 Jul-Aug;26(6):710-2 [16829822.001]
  • [Cites] Am J Ophthalmol. 2007 Aug;144(2):260-5 [17533104.001]
  • [Cites] Curr Eye Res. 2008 Jul;33(7):517-23 [18600484.001]
  • [Cites] Retina. 2003 Dec;23(6):820-46; quiz 895-6 [14707834.001]
  • [Cites] Acta Haematol. 2000;104(1):46-9 [11111123.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):647-52 [11336942.001]
  • [Cites] Retina. 2001;21(3):237-42 [11421013.001]
  • (PMID = 20046700.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789964
  • [Keywords] NOTNLM ; Exudative retinal detachment / Leukemia / Vogt-Koyanagi-Harada disease
  •  go-up   go-down


27. Aldrich MC, Zhang L, Wiemels JL, Ma X, Loh ML, Metayer C, Selvin S, Feusner J, Smith MT, Buffler PA: Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California. Cancer Epidemiol Biomarkers Prev; 2006 Mar;15(3):578-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California.
  • Epidemiologic studies of childhood leukemia have made limited use of tumor genetic characteristics, which may be related to disease etiology.
  • We characterized the cytogenetics of 543 childhood leukemia patients (0-14 years of age) enrolled in the Northern California Childhood Leukemia Study, an approximately population-based study comprised primarily of Hispanics (42%) and non-Hispanic Whites (41%), and compared the cytogenetic profiles between these two ethnic groups.
  • The ploidy levels most frequently observed among acute lymphoblastic leukemia patients were high hyperdiploidy (51-67 chromosomes) and pseudodiploidy (34% and 27%, respectively).
  • Among B-lineage acute lymphoblastic leukemia patients, the percentage of TEL-AML1 translocations was significantly lower in Hispanics (13%) than in non-Hispanic Whites (24%; P = 0.01).
  • The mechanistic basis for this 2-fold variation in frequency of TEL-AML1 may be due to ethnic-specific risk factors or genetics and should be explored further.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. European Continental Ancestry Group / genetics. Genetic Predisposition to Disease / epidemiology. Hispanic Americans / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537719.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Genetic Markers; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


28. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA: Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood; 2008 May 1;111(9):4716-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.
  • Reconstitution of SMPD3 expression in mouse tumor cells lacking the endogenous gene enhanced tumor necrosis factor (TNF)-induced reduction of cell viability.
  • Nucleotide sequencing of the highly conserved SMPD3 gene in a large panel of human cancers revealed mutations in 5 (5%) of 92 acute myeloid leukemias (AMLs) and 8 (6%) of 131 acute lymphoid leukemias (ALLs), but not in other tumor types.
  • Taken together, these observations suggest that disruption of the ceramide pathway may contribute to a subset of human leukemias.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3638-43 [9520418.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochim Biophys Acta. 1999 Apr 19;1438(1):1-17 [10216276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4554-9 [15764706.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):803-5 [16025116.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 9;344(3):900-5 [16631623.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13784-93 [16517606.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1384-96 [17085432.001]
  • [Cites] Science. 2007 Feb 2;315(5812):642-5 [17204608.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):145-6 [17344839.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):501-13 [18068628.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Leukemia. 1995 Jun;9(6):965-71 [7596186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5950-4 [7597059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5895-900 [10823942.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(11):3633-8 [11997500.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41128-39 [12154098.001]
  • [Cites] Cell. 2003 Mar 7;112(5):673-84 [12628187.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] FASEB J. 2004 Jun;18(9):968-70 [15059969.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):25101-11 [15051724.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):604-16 [15286740.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):550-7 [6587018.001]
  • [Cites] Science. 1987 Mar 13;235(4794):1394-9 [3823889.001]
  • [Cites] Nucleic Acids Res. 1988 Aug 11;16(15):7351-67 [3045756.001]
  • [Cites] J Biol Chem. 1989 Nov 15;264(32):19076-80 [2808413.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):484-9 [1845977.001]
  • [Cites] J Biol Chem. 1991 May 5;266(13):8531-9 [1840600.001]
  • [Cites] Leukemia. 1992 Dec;6(12):1250-6 [1453770.001]
  • [Cites] Science. 1993 Feb 12;259(5097):946-51 [8438152.001]
  • [Cites] Nature. 1994 Apr 21;368(6473):753-6 [8152487.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):789-92 [8524414.001]
  • [Cites] Science. 1996 Dec 13;274(5294):1855-9 [8943189.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • (PMID = 18299447.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / P01 CA109901; United States / NCI NIH HHS / CA / CA109901; United States / NCI NIH HHS / CA / CA68484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ceramides; EC 3.1.4.12 / SMPD3 protein, human; EC 3.1.4.12 / Sphingomyelin Phosphodiesterase
  • [Other-IDs] NLM/ PMC2343601
  •  go-up   go-down


29. Ruiz-Argüelles GJ, Fernández-Lara D, Estrada-Gómez R, Manzano C, Ruiz-Delgado GJ, Pérez-Romano B, Ruiz-Argüelles A: Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance. Lab Hematol; 2007;13(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
  • Two main techniques are being used for the detection of minimal residual disease (MRD) in acute leukemia (AL): immunophenotypic analysis and polymerase chain reaction (PCR).
  • (1) acute lymphoblastic leukemia (ALL) patients with MRD (n = 36);.
  • (2) acute myeloblastic leukemia (AML) patients with MRD (n = 13);.
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Neoplasm Recurrence, Local / blood. Neoplasm, Residual / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353179.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


30. Leung KT, Li KK, Sun SS, Chan PK, Ooi VE, Chiu LC: Activation of the JNK pathway promotes phosphorylation and degradation of BimEL--a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis; 2008 Mar;29(3):544-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the JNK pathway promotes phosphorylation and degradation of BimEL--a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemias (T-ALLs) are highly malignant tumors with 20% of patients continues to fail therapy, in part due to chemoresistance of T-ALL cells via largely unknown mechanisms.
  • Here, we showed that lack of Bcl-2-interacting mediator of cell death (Bim)(EL) protein expression, a BH3-only member of the Bcl-2 family proteins, conferred resistance of a T-ALL cell line, Sup-T1, to etoposide-induced apoptosis.
  • Pretreatment of Sup-T1 cells with a specific JNK inhibitor, SP600125, also increased the Bim(EL) level and resensitized the cells to etoposide-induced apoptosis.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Drug Resistance, Neoplasm. Leukemia-Lymphoma, Adult T-Cell / metabolism. MAP Kinase Kinase 4 / metabolism. Membrane Proteins / metabolism. Proto-Oncogene Proteins / metabolism


31. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS: Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 May 1;12(9):2662-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.
  • To determine if Mer expression is ectopic in T-cell acute lymphoblastic leukemia (ALL) and potentially important in leukemogenesis, we analyzed Mer expression in normal human thymocytes and lymphocytes and in pediatric ALL patient samples.
  • Mer expression in 34 T-cell ALL (T-ALL) patient samples was evaluated by reverse transcription-PCR, and Mer protein expression in a separate cohort of 16 patient samples was assayed by flow cytometry and Western blot.
  • CONCLUSIONS: Transforming Mer signals may contribute to T-cell leukemogenesis, and abnormal Mer expression may be a novel therapeutic target in pediatric ALL therapy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675557.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082086; United States / NCI NIH HHS / CA / CA 68346; United States / NCI NIH HHS / CA / P30 CA46934; United States / NCI NIH HHS / CA / T32CA8608604
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Neoplasm; EC 2.7.10.1 / MERTK protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


32. Gao YJ, Zhu XH, Yang Y, Wu Y, Lu FJ, Zhai XW, Wang HS: Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China. Cancer Genet Cytogenet; 2007 Oct 1;178(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China.
  • A series of 92 Chinese children newly diagnosed with acute lymphoblastic leukemia (ALL) were examined for the ETV6-RUNX1 (previously TEL-AML1) fusion gene by using a nested reverse transcriptase-polymerase chain reaction.
  • ETV6-RUNX1 fusion transcripts were detected in 21 of 92 patients (22.8%): 16 with common ALL, 4 with precursor B-cell ALL, and 1 with T-ALL.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / biosynthesis. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / biosynthesis. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / biosynthesis. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889709.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


33. Brugnoletti F, Morris EB, Laningham FH, Patay Z, Pauley JL, Pui CH, Jeha S, Inaba H: Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer; 2009 Feb;52(2):293-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings.
  • Systemic and intrathecal methotrexate (MTX) are integral components of acute lymphoblastic leukemia (ALL) therapy, but can be associated with neurotoxicity.
  • We describe here the case of an adolescent male with T-cell ALL who developed recurrent episodes of subacute neurotoxicity characterized by slurred speech, emotional lability, and hemiparesis after intrathecal MTX administration.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):252-6 [1734087.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1845-50 [3465876.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1356-60 [3875390.001]
  • [Cites] Radiology. 2003 Dec;229(3):659-69 [14576448.001]
  • [Cites] Radiology. 2000 Nov;217(2):331-45 [11058626.001]
  • [Cites] J Child Neurol. 2000 Sep;15(9):573-80 [11019787.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1688-95 [15569732.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):178-84 [17947226.001]
  • [Cites] Blood. 1949 Feb;4(2):160-7 [18107667.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1672-3 [17786701.001]
  • [Cites] Leukemia. 2007 Feb;21(2):238-47 [17170721.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3142-9 [16809737.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):153-7 [16132495.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1263-9 [15891195.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1176-81 [9697870.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2675-82 [8254024.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):544-7 [7776773.001]
  • (PMID = 18831032.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-29; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-29
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS75296; NLM/ PMC2605174
  •  go-up   go-down


34. Launes C, Rives S, Català A, Berrueco R, Toll T, Camós M, Muñoz-Almagro C, García-García JJ, Estella J: Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia. Br J Haematol; 2010 Jun;149(6):874-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia.
  • There are no reports of this disease among paediatric patients with acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Influenza A Virus, H1N1 Subtype. Influenza, Human / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Flu.
  • MedlinePlus Health Information. consumer health - H1N1 Flu (Swine Flu).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2011 Feb;152(4):492-3 [20955407.001]
  • (PMID = 20346006.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 20O93L6F9H / Oseltamivir
  •  go-up   go-down


35. De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, Wlodarska I, Vandenberghe P, Hagemeijer A, Marynen P, Cools J: Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood; 2005 Jun 15;105(12):4849-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
  • The BCR-ABL1 fusion kinase is frequently associated with chronic myeloid leukemia and B-cell acute lymphoblastic leukemia but is rare in T-cell acute lymphoblastic leukemia (T-ALL).
  • Here we describe the identification of another ABL1 fusion, EML1-ABL1, in a T-ALL patient with a cryptic t(9;14)(q34;q32) associated with deletion of CDKN2A (p16) and expression of TLX1 (HOX11).
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 9. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Fusion Proteins, bcr-abl / chemistry. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, T-Cell / pathology. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Base Sequence. Benzamides. Blotting, Western. Cell Line. Cell Survival. DNA, Complementary / metabolism. DNA-Binding Proteins / metabolism. Female. Gene Deletion. Genes, abl. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Karyotyping. Microtubules / metabolism. Milk Proteins / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Models, Genetic. Molecular Sequence Data. Open Reading Frames. Phenotype. Phosphorylation. Piperazines / pharmacology. Polymerase Chain Reaction. Protein Kinase Inhibitors / pharmacology. Protein Structure, Tertiary. Protein-Tyrosine Kinases / metabolism. Pyrimidines / pharmacology. Recombinant Fusion Proteins / metabolism. Retroviridae. Reverse Transcriptase Polymerase Chain Reaction. STAT5 Transcription Factor. Signal Transduction. Time Factors. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15713800.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / EML1-ABL1 fusion protein, human; 0 / Milk Proteins; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Recombinant Fusion Proteins; 0 / STAT5 Transcription Factor; 0 / Trans-Activators; 0 / abl-bcr fusion protein, human; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


36. Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA: Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood; 2009 Jun 11;113(24):6172-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in NOTCH1 are frequently detected in patients with T-cell acute lymphoblastic leukemia (T-ALL) and in mouse T-ALL models.
  • Treatment of mouse or human T-ALL cell lines in vitro with gamma-secretase inhibitors (GSIs) results in growth arrest and/or apoptosis.
  • T-ALL cell lines also exhibit PI3K/mTOR pathway activation, indicating that rapamycin may also have therapeutic benefit.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):138-44 [11248806.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] Toxicol Sci. 2004 Nov;82(1):341-58 [15319485.001]
  • [Cites] Mol Cell Biol. 1989 May;9(5):2124-32 [2501659.001]
  • [Cites] EMBO J. 1990 Oct;9(10):3343-51 [2209547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 [2034676.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1477-88 [1886719.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5462-9 [1922059.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1887-93 [1923511.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1327-33 [1311214.001]
  • [Cites] Blood. 1995 Jul 15;86(2):666-76 [7605997.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5160-6 [8895560.001]
  • [Cites] Cell. 1996 Nov 1;87(3):483-92 [8898201.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5113-9 [8912842.001]
  • [Cites] EMBO J. 1997 May 1;16(9):2408-19 [9171354.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):964-8 [15959516.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93 [16618932.001]
  • [Cites] Blood. 2006 May 15;107(10):4115-21 [16449526.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3023-31 [16407836.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9262-7 [16751266.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1032-7 [17183313.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1083-7 [17183323.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):52-9 [17178457.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):781-4 [17259972.001]
  • [Cites] Chem Biol. 2007 Feb;14(2):209-19 [17317574.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4753-60 [17311993.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [CommentIn] Blood. 2009 Jun 11;113(24):6044-5 [19520812.001]
  • (PMID = 19246562.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899; United States / NCI NIH HHS / CA / CA096899; United States / NIDDK NIH HHS / DK / P30DK32529
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Carrier Proteins; 0 / Cyclic S-Oxides; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MRK 003; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 0 / Tal1 protein, mouse; 0 / Thiadiazoles; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC2699237
  •  go-up   go-down


37. Mello MR, Metze K, Adam RL, Pereira FG, Magalhães MG, Machado CG, Lorand-Metze I: Phenotypic subtypes of acute lymphoblastic leukemia associated with different nuclear chromatin texture. Anal Quant Cytol Histol; 2008 Apr;30(2):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic subtypes of acute lymphoblastic leukemia associated with different nuclear chromatin texture.
  • OBJECTIVE: To determine if phenotypic subtypes of acute lymphoblastic leukemia (ALL) are associated with different nuclear textures.
  • B-precursor ALL was further subdivided by European Group for the Immunological Classification of Leukemias criteria.
  • CONCLUSION: ALL of B- or T-origin presented significant differences in nuclear texture features, probably reflecting different molecular events associated with cell differentiation, gene methylation pattern, apoptosis, and lineage-specific functional events.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561745.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin
  •  go-up   go-down


38. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D: Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol; 2010 Aug 10;28(23):3730-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
  • PURPOSE: Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell transplantation (HSCT).
  • PATIENTS AND METHODS: Overall, 2,255 patients who underwent transplantation for acute leukemia in relapse or with primary induction failure after myeloablative conditioning regimen between 1995 and 2004 were reported to the Center for International Blood and Marrow Transplant Research.
  • RESULTS: The 3-year overall survival (OS) rates were 19% for acute myeloid leukemia (AML) and 16% for acute lymphoblastic leukemia (ALL).
  • HSCT during relapse can achieve long-term survival in selected patients with acute leukemia.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(9):1856-66 [10784626.001]
  • [Cites] Haematologica. 2010 Jun;95(6):989-95 [19951968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(11):1157-63 [11149725.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4290-7 [12920027.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):799-806 [15361903.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] Blood. 1992 Aug 15;80(4):1090-3 [1498326.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1391-5 [7858269.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):271-7 [8819076.001]
  • [Cites] Blood. 1997 Jun 1;89(11):4226-35 [9166868.001]
  • [Cites] Bone Marrow Transplant. 1998 Apr;21(7):673-8 [9578306.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3662-71 [10339472.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14 [15682071.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):157-62 [15937511.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):45-50 [16258531.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1092-9 [16551971.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55 [17067911.001]
  • [Cites] Biom J. 2006 Dec;48(6):1029-40 [17240660.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Blood. 2008 Jul 15;112(2):415-25 [18451310.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):943-8 [10800061.001]
  • (PMID = 20625136.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL069294; United States / NCI NIH HHS / CA / U24 CA076518
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2917308
  •  go-up   go-down


39. DeAngelo DJ, Stone RM: New agents for the treatment of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep; 2008 Jul;3(3):135-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New agents for the treatment of patients with acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) has a bimodal age distribution with a peak occurring during early childhood and a second peak after age 45.
  • [MeSH-major] Nucleosides / chemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Age Factors. Antibodies, Monoclonal / therapeutic use. Asparaginase / chemistry. Asparaginase / therapeutic use. Disease-Free Survival. Enzyme Inhibitors / therapeutic use. HSP90 Heat-Shock Proteins / antagonists & inhibitors. HSP90 Heat-Shock Proteins / metabolism. Humans. Liposomes / chemistry. Liposomes / therapeutic use. Methotrexate / analogs & derivatives. Methotrexate / therapeutic use. Receptors, Notch / antagonists & inhibitors. Receptors, Notch / metabolism. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Blood. 2007 Apr 1;109 (7):2744-50 [17132721.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4674-81 [14581336.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):69-72 [10690390.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Hematol J. 2003;4(1):47-53 [12692520.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):591-7 [16988580.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1556-64 [9716583.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4164-7 [17264295.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Mini Rev Med Chem. 2007 Sep;7(9):976-83 [17897085.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Cancer. 2007 May 15;109(10):2058-67 [17407135.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2645-51 [16688777.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Ann Hematol. 2004 Apr;83(4):201-5 [14648023.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1216-30 [10506707.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Br J Haematol. 2007 Nov;139(3):425-8 [17910632.001]
  • [Cites] Blood. 2007 Jul 15;110(2):727-34 [17405907.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3068-70 [12842984.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] Blood. 2006 Jul 1;108(1):45-51 [16403905.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2734-9 [11929760.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3214-8 [17209054.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):120-7 [16331634.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):695-8 [15160941.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):697-705 [10080616.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):731-3 [15160947.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3674-81 [16902153.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):189-93 [10761754.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4253-60 [16131572.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • (PMID = 20425458.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Enzyme Inhibitors; 0 / HSP90 Heat-Shock Proteins; 0 / Liposomes; 0 / Nucleosides; 0 / Receptors, Notch; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


40. Kober T, Skoetz N, Trelle S, Bohlius J, Engert A, Cochrane Haematological Malignancies Group: Third biannual report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst; 2005 Aug 17;97(16):E2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hematologic Neoplasms / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Burkitt Lymphoma / therapy. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Humans. Leukemia, Myeloid, Acute / therapy. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Mantle-Cell / therapy. Multicenter Studies as Topic. Multiple Myeloma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prospective Studies. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106014.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 0
  •  go-up   go-down


41. Lancioni C, LaBeaud AD, Esper F, Abughali N, Auletta J: Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Dec 15;53(7):1318-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia.
  • In this report we describe a case of primary pulmonary tuberculosis (TB) in a boy with precursor B-cell acute lymphoblastic leukemia (ALL) and review the pertinent literature.
  • [MeSH-major] Fever of Unknown Origin / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tuberculosis, Pulmonary / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Tuberculosis.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. ISONIAZID .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ETHAMBUTOL .
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • Hazardous Substances Data Bank. PYRAZINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19618457.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 04079A1RDZ / Cytarabine; 2KNI5N06TI / Pyrazinamide; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83905-01-5 / Azithromycin; 8G167061QZ / Ethambutol; 8N3DW7272P / Cyclophosphamide; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


42. Hildebrandt P, Richards AM: Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol; 2008 Feb 4;101(3A):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension.
  • Although the current value of amino-terminal pro-B-type natriuretic peptides (NT-proBNP) to generally screen populations of "apparently well patients" remains promising but still undefined, the use of NT-proBNP to screen patients at high risk for heart disease (such as elderly patients, or patients with diabetes mellitus, hypertension, or known coronary artery disease) appears logical and is supported by data.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243853.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 19
  •  go-up   go-down


43. Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S: NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood; 2006 Nov 15;108(10):3556-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia (T-ALL) has recently been identified as a possible target for imatinib and related tyrosine kinase inhibitors, but exact data regarding the prognostic impact and frequency of the several putative NUP214-ABL1 mRNA transcripts are still missing.
  • Eleven (3.9%) patients were NUP214-ABL1 positive, and 5 different transcripts were observed; 8 patients had a thymic immunophenotype, 1 had an early T-cell immunophenotype, and 2 had a mature T-cell immunophenotype.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / genetics. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins c-abl / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16873673.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / NUP214 protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl
  •  go-up   go-down


44. Nakasone H, Kida M, Iki S, Usuki K: Lower leukocytes at initial diagnosis may predict poor outcome of very late relapse of acute lymphoblastic leukemia. Leuk Res; 2008 Apr;32(4):659-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower leukocytes at initial diagnosis may predict poor outcome of very late relapse of acute lymphoblastic leukemia.
  • We have reported a rare case of acute lymphoblastic leukemia (ALL) recurring 19 years after the first presentation.
  • Since 1984, 36 relapse cases 10 years or more after the first diagnosis have been reported.
  • [MeSH-major] Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850867.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W: Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother; 2008 Feb;57(2):233-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
  • This study investigated the pro-apoptotic potential of a novel TRAIL fusion protein designated scFvCD19:sTRAIL, consisting of a CD19-specific single-chain Fv antibody fragment (scFv) fused to the soluble extracellular domain of TRAIL (sTRAIL).
  • Potent apoptosis was induced by scFvCD19:sTRAIL in several CD19-positive tumor cell lines, whereas normal blood cells remained unaffected.
  • Simultaneous treatment of CD19-positive cell lines with scFvCD19:sTRAIL and valproic acid (VPA) or Cyclosporin A induced strongly synergistic apoptosis.
  • Treatment of patient-derived acute B-lymphoblastic leukemia (B-ALL) and chronic B-lymphocytic leukemia (B-CLL) cells resulted in strong tumoricidal activity that was further enhanced by combination with VPA.
  • The pre-clinical data presented here warrant further investigation of scFvCD19:sTRAIL as a potential new therapeutic agent for CD19-positive B-lineage malignancies.
  • [MeSH-major] Antigens, CD19. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Leukemia, B-Cell / drug therapy. Recombinant Fusion Proteins / pharmacology. TNF-Related Apoptosis-Inducing Ligand

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665197.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antineoplastic Agents; 0 / Immunoglobulin Fragments; 0 / Recombinant Fusion Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 614OI1Z5WI / Valproic Acid; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


46. Zhang Y, Wang Y, Huang L, Chen D, Tao Y, Yuan Z: Effects of cooking and storage on residues of cyadox in chicken muscle. J Agric Food Chem; 2005 Dec 14;53(25):9737-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heat stabilities of cyadox (CYX) and its two metabolites, 1,4-bisdesoxycyadox (BDCYX) and quinoxaline-2-carboxylic acid (QCA), in water, cooking oil, and as incurred residues in chicken muscle were investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332123.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinoxalines; 65884-46-0 / cyadox
  •  go-up   go-down


47. Fu JF, Liang DC, Shih LY: Analysis of acute leukemias with MLL/ENL fusion transcripts: identification of two novel breakpoints in ENL. Am J Clin Pathol; 2007 Jan;127(1):24-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of acute leukemias with MLL/ENL fusion transcripts: identification of two novel breakpoints in ENL.
  • t(11;19)(q23;p13.3); is one of the common chromosomal translocations in acute leukemias involving MLL rearrangements.
  • In a study of acute leukemias, 148 patients were identified to have MLL rearrangements by Southern blot analysis.
  • Reverse transcriptase-polymerase chain reaction (RT-PCR) assay, using primer sets covering the 2 previously described breakpoints at exons 2 and 7 of ENL detected 11 samples harboring MLL/ENL. complementary DNA panhandle PCR further identified 4 additional cases with novel breakpoints in ENL at exon 4 or 6.
  • Of 15 patients with MLL/ENL, 7 had precursor B-cell acute lymphoblastic leukemia, 4 had T-cell acute lymphoblastic leukemia, and 4 had acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Oncogene Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Infant. Infant, Newborn. Male. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145626.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / MLLT1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


48. Yokoyama Y, Grünebach F, Schmidt SM, Heine A, Häntschel M, Stevanovic S, Rammensee HG, Brossart P: Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res; 2008 Sep 1;14(17):5503-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells.
  • Using microarray and reverse transcription-PCR analysis, we found matrix metalloproteinase (MMP)-7 to be extensively up-regulated in renal cell carcinomas and expressed in a broad variety of malignant cells.
  • EXPERIMENTAL DESIGN: To analyze the possible use of MMP-7 as a tumor-associated antigen, specific CTLs were induced using monocyte-derived dendritic cells electroporated with MMP-7-mRNA.
  • In addition, to better characterize the fine specificity of these CTLs, MMP-7 MHC class I ligands were isolated and characterized in renal cell carcinoma tissue, which overexpressed MMP-7, by mass spectrometry-based peptide sequencing.
  • RESULTS: The induced CTLs elicited an antigen-specific and HLA-restricted cytolytic activity against tumor cells endogenously expressing the MMP-7 protein.
  • Furthermore, we were able to induce MMP-7-specific CTLs using peripheral blood mononuclear cells from a patient with acute lymphoblastic leukemia capable of recognizing the autologous leukemic blasts while sparing nonmalignant cells.
  • CONCLUSIONS: Our study describes the identification of a novel broadly expressed T-cell epitope derived from the MMP-7 protein that represents an interesting candidate to be applied in immunotherapies of human malignancies targeting both tumor cells and neovascularization.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Carcinoma, Renal Cell / immunology. Kidney Neoplasms / immunology. Matrix Metalloproteinase 7 / isolation & purification
  • [MeSH-minor] Cell Line, Tumor. Electroporation. Epitopes. Epitopes, T-Lymphocyte / immunology. HLA-A3 Antigen / immunology. Humans. T-Lymphocytes / immunology. T-Lymphocytes, Cytotoxic / immunology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18765542.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / Epitopes, T-Lymphocyte; 0 / HLA-A3 Antigen; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


49. Robazzi TC, Barreto JH, Silva LR, Santiago MB, Mendonça N: Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil. J Pediatr Hematol Oncol; 2007 Sep;29(9):622-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil.
  • OBJECTIVE: This study was to determine the prevalence and characteristics of the osteoarticular manifestations on initial clinical presentation of acute leukemias (ALs) on childhood in the state of Bahia, Brazil.
  • RESULTS: Acute lymphocytic leukemia (ALL) was diagnosed in 313 (77.1%) patients and acute myeloid leukemia (AML), in 93 (22.9%) patients, including 241 males (59.4%) and 165 females (40.6%).
  • The most common presenting features were fever (18.5%), musculoskeletal diffuse tenderness (15.0%), pallor (11.4%), and leg tenderness (5.7%).
  • Prior referral to our center, the most frequent initial diagnosis was anemia (15.8%), leukemia (15.0%), amygdalitis (3.7%), and rheumatic fever (2.7%).
  • CONCLUSIONS: AL should be considered on the differential diagnosis of osteoarticular symptoms of unknown etiology in children.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Osteoarthritis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Brazil. Child. Child, Preschool. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805037.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Pan JL, Xue YQ, Jiang HY, Zhu YJ, Ma L, Li TY, Wang Y, Wu YF: [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)].
  • OBJECTIVE: To investigate the laboratory and clinical features of 7 cases of acute lymphoblastic leukemia (ALL) with dic(7;9) (pll;pll).
  • FISH using chromosome 7-specific alpha-satellite DNA probe and chromosome 9-specific alpha-satellite DNA probe and chromosome painting using whole chromosome 7 and 9 paints probes were performed respectively.
  • RESULTS: Seven (0.88%) of 800 ALL patients were found to have dic(7;9) abnormality.
  • Among them, dic(7;9) was the sole abnormality in 2 cases, t(9;22), other additional aberrations besides dic(7;9) in 4 cases and dic (7;9) with other abnormalities but no t(9;22) in one case.
  • CONCLUSION: dic(7;9) was a rare, but recurrent chromosome abnormality in ALL and had some clinical and laboratory features.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383241.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


51. Aljurf M, Zaidi SZ: Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant; 2005 Oct;11(10):739-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies.
  • Adult T-cell lymphoblastic lymphoma is a relatively rare aggressive type of non-Hodgkin lymphoma with frequent involvement of extranodal sites.
  • The collective experience in the management of adult T-cell lymphoblastic lymphoma suggests a good outcome for patients with no adverse prognostic factors who are treated with an acute lymphocytic leukemia-like treatment strategy.
  • Patients with adverse prognostic features should be considered for more aggressive therapy-specifically, high-dose chemotherapy and hematopoietic stem cell transplantation.
  • This article will attempt to review the current status of chemotherapy treatment programs and the relative merits of the different hematopoietic stem cell transplantation programs in this disease, particularly in relation to the pathologic and clinical features that correlate with disease prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182175.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 114
  •  go-up   go-down


52. Mansur MB, Emerenciano M, Brewer L, Sant'Ana M, Mendonça N, Thuler LC, Koifman S, Pombo-de-Oliveira MS: SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome. Leuk Lymphoma; 2009 Aug;50(8):1318-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome.
  • SIL-TAL1 fusion gene and the ectopic expression of HOX11L2 are common molecular abnormalities in T-cell acute lymphoblastic leukemia (T-ALL).
  • [MeSH-major] Homeodomain Proteins / analysis. Oncogene Proteins, Fusion / blood. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562638.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / SIL-TAL1 fusion protein, human; 0 / TLX3 protein, human
  •  go-up   go-down


53. Li ZG, Zhao W, Wu MY, Hu YM: [Variant fusion transcript in ALL children with E2A-PBX1 fusion gene positive]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun;14(3):516-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study was aimed to investigate the expression of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia (ALL).
  • The primers located at different sites of E2A and PBX1 gene were used to screen for the fusion gene in 410 children with ALL, including 362 cases of B cell ALL and 48 cases of T cell ALL.
  • Furthermore, all the positive cases expressed a variant type of fusion transcript.
  • Analyses with BLASTn indicated that the variant type of transcript retained the open reading frame.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800933.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; 146150-85-8 / E2A-Pbx1 fusion protein
  •  go-up   go-down


54. Chen J, Jette C, Kanki JP, Aster JC, Look AT, Griffin JD: NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia; 2007 Mar;21(3):462-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1-induced T-cell leukemia in transgenic zebrafish.
  • Activating mutations in the NOTCH1 gene have been found in about 60% of patients with T-cell acute lymphoblastic leukemia (T-ALL).
  • In order to study the molecular mechanisms by which altered Notch signaling induces leukemia, a zebrafish model of human NOTCH1-induced T-cell leukemia was generated.
  • Seven of sixteen mosaic fish developed a T-cell lymphoproliferative disease at about 5 months.
  • These neoplastic cells extensively invaded tissues throughout the fish and caused an aggressive and lethal leukemia when transplanted into irradiated recipient fish.
  • However, stable transgenic fish exhibited a longer latency for leukemia onset.
  • When the stable transgenic line was crossed with another line overexpressing the zebrafish bcl2 gene, the leukemia onset was dramatically accelerated, indicating synergy between the Notch pathway and the bcl2-mediated antiapoptotic pathway.
  • Reverse transcription-polymerase chain reaction analysis showed that Notch target genes such as her6 and her9 were highly expressed in NOTCH1-induced leukemias.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Leukemia-Lymphoma, Adult T-Cell / etiology. Proto-Oncogene Proteins c-bcl-2 / physiology. Receptor, Notch1 / physiology
  • [MeSH-minor] Animals. Animals, Genetically Modified. Apoptosis. Basic Helix-Loop-Helix Transcription Factors / physiology. Female. Gamma Rays. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor. Genes, bcl-2. Humans. Male. Mosaicism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Neoplasm Transplantation. Oncogenes. Radiation Chimera. Radiation Tolerance. Recombinant Fusion Proteins / physiology. Signal Transduction. Time Factors. Zebrafish. Zebrafish Proteins / physiology

  • COS Scholar Universe. author profiles.
  • SciCrunch. ZFIN: Data: Gene Expression .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252014.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-36167; United States / NCI NIH HHS / CA / CA-68484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Her6 protein, zebrafish; 0 / NOTCH1 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptor, Notch1; 0 / Recombinant Fusion Proteins; 0 / Zebrafish Proteins; 0 / her9 protein, zebrafish
  •  go-up   go-down


55. Zanrosso CW, Hatagima A, Emerenciano M, Ramos F, Figueiredo A, Félix TM, Segal SL, Giugliani R, Muniz MT, Pombo-de-Oliveira MS: The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk Res; 2006 Apr;30(4):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population.
  • In order to investigate the influence of two polymorphisms in the MTHFR gene, 677C>T and 1298A>C, on the risk of acute lymphoblastic leukemia (ALL) we performed a case-control study in children from different Brazilians' regions.
  • Our investigation provides interesting data concerning the opposite effect of A1298C polymorphisms, particularly in the light of relatively scarce data regarding the MTHFR role in leukemia susceptibility in different populations.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leuk Res. 2009. doi: 10.1016/j.leukres.2009.01.019. Guigliani, Roberto [corrected to Giugliani, Roberto]
  • [ErratumIn] Leuk Res. 2009 Jul;33(7):1009
  • (PMID = 16182363.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


56. Mazzoleni S, Putti MC, Simioni P, Sainati L, Tormene D, Manara R, Carli M: Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature. Blood Coagul Fibrinolysis; 2005 Jan;16(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature.
  • This paper describes the case of a male child with acute lymphoblastic leukemia who developed cerebral sinovenous thrombosis on day 6 of induction therapy with intrathecal methotrexate and methylprednisolone.
  • [MeSH-major] Activated Protein C Resistance / drug therapy. Fibrinolytic Agents / administration & dosage. Nadroparin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Prothrombin. Sinus Thrombosis, Intracranial / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Prothrombin.
  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15650545.001).
  • [ISSN] 0957-5235
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Nadroparin; 9001-26-7 / Prothrombin
  •  go-up   go-down


57. Gilham C, Peto J, Simpson J, Roman E, Eden TO, Greaves MF, Alexander FE, UKCCS Investigators: Day care in infancy and risk of childhood acute lymphoblastic leukaemia: findings from UK case-control study. BMJ; 2005 Jun 4;330(7503):1294
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Day care in infancy and risk of childhood acute lymphoblastic leukaemia: findings from UK case-control study.
  • OBJECTIVE: To test the hypothesis that reduced exposure to common infections in the first year of life increases the risk of developing acute lymphoblastic leukaemia.
  • PARTICIPANTS: 6305 children (aged 2-14 years) without cancer; 3140 children with cancer (diagnosed 1991-6), of whom 1286 had acute lymphoblastic leukaemia (ALL).
  • Similar results were obtained for B cell precursor common ALL and other subgroups, as well as for cases diagnosed above and below age 5 years.
  • CONCLUSION: These results support the hypothesis that reduced exposure to infection in the first few months of life increases the risk of developing acute lymphoblastic leukaemia.
  • [MeSH-major] Child Day Care Centers / statistics & numerical data. Communicable Diseases / epidemiology. Environmental Exposure / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Child Care.
  • MedlinePlus Health Information. consumer health - Infectious Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1073-102 [10737392.001]
  • [Cites] Diabet Med. 2000 Mar;17(3):236-42 [10784230.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):956-8 [10970701.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1136-44 [11130619.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):350-5 [11875698.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Hum Mol Genet. 2002 Jul 1;11(14):1585-97 [12075003.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):511-2 [12189546.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):590-4 [3463201.001]
  • [Cites] Pediatrics. 1987 Jan;79(1):55-60 [3797171.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] BMJ. 1988 Oct 29;297(6656):1070 [3143433.001]
  • [Cites] Acta Paediatr Scand. 1990 Aug-Sep;79(8-9):838-46 [2239281.001]
  • [Cites] Leukemia. 1993 Mar;7(3):349-60 [8445941.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] Am J Public Health. 1995 Aug;85(8 Pt 1):1109-12 [7625505.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Lancet. 1999 Feb 6;353(9151):450-4 [9989715.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):175-8 [10487630.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):749-59 [15763652.001]
  • [CommentIn] BMJ. 2005 Jun 4;330(7503):1279-80 [15933336.001]
  • (PMID = 15849205.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC558199
  •  go-up   go-down


58. Whitlock JA: Down syndrome and acute lymphoblastic leukaemia. Br J Haematol; 2006 Dec;135(5):595-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down syndrome and acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia in children with Down syndrome (ALL-DS) is characterised by unique clinical and biological features.
  • [MeSH-major] Down Syndrome / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054672.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 U10 CA098543-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 77
  •  go-up   go-down


59. Ishizawa J, Fujita H, Iguchi M, Tachibana T, Taguchi J, Ishigatsubo Y: Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir. Int J Hematol; 2007 Apr;85(3):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).
  • A diagnosis of visceral varicella-zoster disease was made, and early intravenous ACV therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.
  • [MeSH-minor] Adult. Cord Blood Stem Cell Transplantation / adverse effects. DNA, Viral / blood. DNA, Viral / drug effects. Female. Humans. Injections, Intravenous. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect. 2003 Aug;47(2):133-8 [12860147.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):1003-5 [10800071.001]
  • [Cites] Lancet. 2001 Jun 30;357(9274):2101-2 [11445106.001]
  • [Cites] J Infect Dis. 1985 Dec;152(6):1172-81 [3905982.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2568-73 [10878045.001]
  • [Cites] Bone Marrow Transplant. 1995 May;15(5):805-7 [7670413.001]
  • [Cites] Intern Med. 2004 Sep;43(9):861-4 [15497526.001]
  • (PMID = 17483062.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; X4HES1O11F / Acyclovir
  •  go-up   go-down


60. Ni X, Shen ZX, Chen FY, Liang H, Tang JY, Lu FJ, Wang C, Shao JB, Hou J, Zou SH, Wang JM: [An epidemiological survey of acute lymphocytic leukemia from 2002 to 2006 in Shanghai.]. Zhonghua Xue Ye Xue Za Zhi; 2010 Jan;31(1):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An epidemiological survey of acute lymphocytic leukemia from 2002 to 2006 in Shanghai.].
  • OBJECTIVE: To analyse the epidemiological data of acute lymphoblastic leukemia (ALL) in Shanghai.
  • Genetic examination revealed that chromosome aberration of t(9;22) was the most common one.
  • [MeSH-major] Immunophenotyping. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302772.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


61. Zhao Y, Yu L, Wang QS, Li HH, Bo J, Wang SH, Jin HJ, Lou FD: [Id4 gene methylation for detection of minimal residual disease in acute leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2006 May;27(5):298-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Id4 gene methylation for detection of minimal residual disease in acute leukemia].
  • OBJECTIVE: To evaluate the possibility of Id4 gene promoter methylation as a biomarker for minimal residual disease (MRD) detection in acute leukemia.
  • METHODS: Methylation specific-PCR technique was used to detect Id4 gene methylation in samples with different percentages of leukemia cells from leukemia cell line and bone marrows from leukemia patients in complete remission (CR).
  • RESULTS: Id4 gene methylation could be detected in samples containing 1% or lower leukemia cells.
  • Frequency of Id4 gene methylation in acute lymphoblastic leukemia (ALL) patients in CR was 64.3% being higher than that in acute myeloid leukemia (AML) patients in CR.
  • CONCLUSION: Id4 gene promoter methylation is a candidate of biomarker for MRD detection in acute leukemias.
  • [MeSH-major] DNA Methylation. Inhibitor of Differentiation Proteins / genetics. Leukemia / diagnosis. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Cell Line. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Promoter Regions, Genetic / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875575.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins
  •  go-up   go-down


62. French D, Yang W, Hamilton LH, Neale G, Fan Y, Downing JR, Cox NJ, Pui CH, Evans WE, Relling MV: Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS One; 2008 May 14;3(5):e2144
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs.
  • We quantified expression of 11,873 genes in paired samples of primary leukemia cells and normal leukocytes from 92 patients with acute lymphoblastic leukemia (ALL).
  • In an independent set of 134 patients with ALL, 14 of these 20 genes were validated as having expression related to cis-SNPs, as were 9 of 20 genes in a second validation set of HapMap cell lines.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Physiol Genomics. 2000 Apr 27;2(3):143-7 [11015593.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):383-91 [11279519.001]
  • [Cites] Physiol Genomics. 2001 Dec 21;7(2):97-104 [11773596.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1896-901 [12578971.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):422-5 [12567189.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):297-302 [12646919.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] Genomics. 2004 Jun;83(6):980-8 [15177552.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Nature. 2004 Aug 12;430(7001):743-7 [15269782.001]
  • [Cites] Am J Hum Genet. 2004 Dec;75(6):1094-105 [15514893.001]
  • [Cites] Genome Biol. 2005;6(3):R22 [15774023.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Hum Mol Genet. 2005 Jun 15;14(12):1621-9 [15857854.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Physiol Genomics. 2005 Aug 11;22(3):402-11 [16014386.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] BMC Genomics. 2006;7:31 [16504025.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e78 [16362079.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W369-73 [16845028.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Cell Cycle. 2006 Nov;5(22):2613-25 [17172834.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D716-20 [17151077.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):226-31 [17206142.001]
  • [Cites] Science. 2007 Feb 9;315(5813):848-53 [17289997.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Pharmacogenet Genomics. 2007 Jun;17(6):447-50 [17502836.001]
  • [Cites] Nature. 2007 Jun 14;447(7146):799-816 [17571346.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):427-37 [17701890.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1217-24 [17873874.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1208-16 [17873875.001]
  • [Cites] BMC Genomics. 2007;8:296 [17727713.001]
  • (PMID = 18478092.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA070089; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / T32-CA070089; United States / NCI NIH HHS / CA / R01 CA078224; United States / NIGMS NIH HHS / GM / U01GM61374; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA78224; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01 GM061374; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / CA51001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2374895
  •  go-up   go-down


63. Cogulu O, Karapinar DY, Karaca E, Aydinok Y, Ozkinay F: Unusual course of an acute lymphoblastic leukemia case with i(9q) as a sole cytogenetic abnormality. Leuk Res; 2006 Nov;30(11):1461-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual course of an acute lymphoblastic leukemia case with i(9q) as a sole cytogenetic abnormality.
  • Chromosomal changes are necessary in determining the classification, prognosis and using the appropriate therapeutic regimen in acute leukemia.
  • Isochromosomes are uncommon chromosome aberations in childhood acute lymphoblastic leukemia (ALL) and the effect of i(9q) is not well established.
  • We present an 8-year-old male case of pre-B ALL who has an unusual course at diagnosis.
  • In the following two hospitalizations no blastic cell was observed and transfused with a pack of erythrocyte suspension each time.
  • In the fourth hospitalization, bone marrow aspiration revealed L1 type of lymphoid blast cell infiltration.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 9 / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Diagnosis, Differential. Erythrocyte Transfusion. Follow-Up Studies. Humans. Karyotyping. Male. Parvoviridae Infections / diagnosis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564090.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


64. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J: Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies. Acta Paediatr; 2006 Jun;95(6):701-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies.
  • AIM: To investigate the possible relationship between serum levels and avidities of antibodies against tetanus toxoid (TT) and Haemophilus influenzae type b (Hib) in children that were vaccinated after treatment for childhood acute lymphoblastic leukaemia (ALL).
  • Antibody levels were analysed at three time points: At diagnosis of ALL, after cessation of treatment before vaccination and three weeks after vaccination.
  • Avidity was measured twice, with a thiocyanate elution assay, at diagnosis of ALL and three weeks after vaccination.
  • [MeSH-major] Antibodies, Bacterial / immunology. Antibody Affinity. Haemophilus Vaccines / immunology. Haemophilus influenzae / immunology. Polysaccharides, Bacterial / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology

  • Genetic Alliance. consumer health - Tetanus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754551.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Haemophilus Vaccines; 0 / Haemophilus influenzae type b polysaccharide vaccine; 0 / Polysaccharides, Bacterial; 0 / Tetanus Toxoid
  •  go-up   go-down


65. Vaskova M, Fronkova E, Starkova J, Kalina T, Mejstrikova E, Hrusak O: CD44 and CD27 delineate B-precursor stages with different recombination status and with an uneven distribution in nonmalignant and malignant hematopoiesis. Tissue Antigens; 2008 Jan;71(1):57-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 and CD27 delineate B-precursor stages with different recombination status and with an uneven distribution in nonmalignant and malignant hematopoiesis.
  • The expression of CD27 and CD44 correlate with the genotype of B-precursor acute lymphoblastic leukemia (ALL).
  • Although CD27 is known as a marker of mature memory B cells, we recently showed that CD27 is also expressed by malignant and nonmalignant B precursors.
  • Here, we show that CD27 and CD44 delineate stages of B-precursor development.
  • These cells correspond to TEL/AML1(pos) ALL (1/4 pediatric B-precursor ALL).
  • Despite their presumably high proliferation potential, 27/44DP cells rarely dominate in leukemia.
  • At 44SP stage, which corresponds to TEL/AML1(neg) leukemias, RAG-1 is reexpressed and Ig light chain gene starts to be rearranged.
  • [MeSH-major] Antigens, CD27 / physiology. Antigens, CD44 / physiology. Gene Rearrangement, B-Lymphocyte / immunology. Leukemia, B-Cell / immunology. Lymphopoiesis / immunology. Precursor Cells, B-Lymphoid / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005092.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Antigens, CD44
  •  go-up   go-down


66. Liu Y, Zhu P, Hu YM: [Epitopes recognized by cytotoxic T lymphocytes in immunoglobulin heavy chain variable regions expressed by B-cell acute lymphoblastic leukemia]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epitopes recognized by cytotoxic T lymphocytes in immunoglobulin heavy chain variable regions expressed by B-cell acute lymphoblastic leukemia].
  • The frequency of QLVQSGAEV-specific CD8+ T cells in a healthy HLA-A*0201+ donor peripheral blood increased from 1.6% and 82.6% after two-round and 3-round stimulations, respectively.
  • These peptides are capable of inducing specific CD8+ T cells to activate and proliferate.
  • [MeSH-major] Burkitt Lymphoma / immunology. CD8-Positive T-Lymphocytes / immunology. Epitopes, T-Lymphocyte / immunology. Immunoglobulin Heavy Chains / immunology. Immunoglobulin Variable Region / immunology
  • [MeSH-minor] Adolescent. Cell Proliferation. Child. Child, Preschool. Gene Rearrangement. HLA-A Antigens / immunology. HLA-A Antigens / metabolism. HLA-A2 Antigen. Humans. Infant. Oligopeptides / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946551.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Epitopes, T-Lymphocyte; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Oligopeptides
  •  go-up   go-down


67. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr: Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J; 2010 Apr;159(4):532-538.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
  • BACKGROUND: Serial measurements of N-terminal pro-B type natriuretic peptide (NT-proBNP) provide prognostic information in patients with chronic heart failure (HF).
  • CONCLUSIONS: The Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study will test the hypothesis that therapy guided by NT-proBNP concentrations will be superior to standard of care HF management (www.clinicaltrials.gov identifier NCT00351390).

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20362709.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00351390
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


68. Khan G: High incidence of Epstein-Barr virus infection in childhood acute lymphocytic leukemia. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):890-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Epstein-Barr virus infection in childhood acute lymphocytic leukemia.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Indian J Pathol Microbiol. 2010 Jan-Mar;53(1):63-7 [20090225.001]
  • (PMID = 21045472.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] India
  •  go-up   go-down


69. Fujii S, Miyata A, Takeuchi M, Yoshino T: [Acute lymphoblastic leukemia (L3) with t(2;3)(p12;q27), t(14;18)(q32;q21), and t(8;22)(q24;q11)]. Rinsho Ketsueki; 2005 Feb;46(2):134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia (L3) with t(2;3)(p12;q27), t(14;18)(q32;q21), and t(8;22)(q24;q11)].
  • A biopsy led to the diagnosis of lymphoid malignancy.
  • The malignant cells showed a B-cell immunophenotype.
  • Karyotyping of the bone marrow at relapse revealed a t(8;22) in addition to t(14;18) and t(2;3), which led to a diagnosis of acute lymphoblastic leukemia (ALL)-L3 (FAB).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447707.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Hartman A, te Winkel ML, van Beek RD, de Muinck Keizer-Schrama SM, Kemper HC, Hop WC, van den Heuvel-Eibrink MM, Pieters R: A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Jul;53(1):64-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia.
  • BACKGROUND: Reduced bone mineral density (BMD), altered body composition, impaired motor performance and passive ankle dorsiflexion are side effects of acute lymphoblastic leukemia (ALL) treatment.
  • PROCEDURE: At diagnosis we randomized 51 ALL patients (median age: 5.4 years) into a group receiving a 2-year exercise program or a control group receiving standard care.
  • [MeSH-major] Bone Density. Bone Diseases, Metabolic / prevention & control. Exercise Therapy / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


71. Kato Y, Takano Y, Kobayashi M, Ito F, Hara T, Yanagisawa T, Hoshi Y, Eto Y: Retinochoroidal infarction during the treatment of acute lymphoblastic leukemia. Pediatr Int; 2006 Oct;48(5):495-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinochoroidal infarction during the treatment of acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Choroid / blood supply. Infarction / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retinal Vessels

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970790.001).
  • [ISSN] 1328-8067
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


72. Mandrell BN, Pritchard M: Understanding the clinical implications of minimal residual disease in childhood leukemia. J Pediatr Oncol Nurs; 2006 Jan-Feb;23(1):38-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the clinical implications of minimal residual disease in childhood leukemia.
  • Improved laboratory techniques now allow a more sensitive detection of leukemia cells at designated intervals throughout therapy.
  • Using flow cytometry and polymerase chain reaction, it is possible to detect 1 leukemic cell among 10(4) normal cells (1 leukemia cell in 10,000 normal cells), representing a 100-fold greater sensitivity than morphological examination in acute lymphoblastic leukemia (ALL).
  • Recently, it has been shown that the molecular presence of persistent acute lymphoblastic leukemia at the end of remission therapy is a poor indicator of clinical outcome.
  • Now similar studies are being performed in acute myeloid leukemia (AML).
  • While the sensitivity using flow cytometry is less in AML than in ALL (able to detect 1 leukemic cell among 1000 normal cells in AML), persistent or minimal residual AML provides the clinician guidance with future treatment recommendations.
  • Therefore, it is imperative that the nurse have an understanding of the newer techniques to study residual leukemia and their clinical implications for patients and their families.
  • [MeSH-major] Leukemia, Myeloid / pathology. Neoplasm, Residual / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689404.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


73. Safa M, Kazemi A, Zand H, Azarkeivan A, Zaker F, Hayat P: Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Apoptosis; 2010 Feb;15(2):196-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues.
  • Exposure of cells to chemotherapeutic drug doxorubicin, a DNA-damaging agent, induces an increase in the levels and activity of the wild-type p53 protein.
  • Here we show that elevation of cAMP in pre-B acute lymphoblastic leukemia NALM-6 cells significantly attenuated phosphorylation state of p53 at Ser6, Ser9, Ser15, Ser20, Ser37, Ser46 and Ser392 upon exposure to doxorubicin.
  • [MeSH-major] Apoptosis / drug effects. Cyclic AMP / pharmacology. Doxorubicin / pharmacology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Serine / metabolism
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Caspase 3 / metabolism. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Checkpoint Kinase 2. DNA Damage. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Leukemic / drug effects. Humans. Intracellular Space / drug effects. Intracellular Space / metabolism. Okadaic Acid / pharmacology. Phosphoprotein Phosphatases / metabolism. Phosphorylation / drug effects. Phosphoserine / metabolism. Protein Phosphatase 1 / metabolism. Protein Phosphatase 2 / metabolism. Protein-Serine-Threonine Kinases / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism. bcl-2-Associated X Protein / metabolism

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. OKADAIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882354.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 17885-08-4 / Phosphoserine; 1W21G5Q4N2 / Okadaic Acid; 452VLY9402 / Serine; 80168379AG / Doxorubicin; E0399OZS9N / Cyclic AMP; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.16 / Protein Phosphatase 1; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.1.3.16 / protein phosphatase 2C; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


74. Slape C, Hartung H, Lin YW, Bies J, Wolff L, Aplan PD: Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res; 2007 Jun 1;67(11):5148-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The t(2;11)(q31;p15) chromosomal translocation results in a fusion between the NUP98 and HOXD13 genes and has been observed in patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia.
  • We previously showed that expression of the NUP98-HOXD13 (NHD13) fusion gene in transgenic mice results in an invariably fatal MDS; approximately one third of mice die due to complications of severe pancytopenia, and about two thirds progress to a fatal acute leukemia.
  • In the present study, we used retroviral insertional mutagenesis to identify genes that might collaborate with NHD13 as the MDS transformed to an acute leukemia.
  • The onset of leukemia was accelerated, suggesting a synergistic effect between the NHD13 transgene and the genes neighboring retroviral insertion events.
  • We identified numerous common insertion sites located near protein-coding genes and confirmed dysregulation of a subset of these by expression analyses.
  • Among these genes were Meis1, a known collaborator of HOX and NUP98-HOX fusion genes, and Mn1, a transcriptional coactivator involved in human leukemia through fusion with the TEL gene.
  • Of note, we identified a common insertion site that was >100 kb from the nearest coding gene, but within 20 kb of the miR29a/miR29b1 microRNA locus.
  • [MeSH-major] Homeodomain Proteins / genetics. Leukemia, Myeloid / genetics. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / genetics. Cloning, Molecular. Ether-A-Go-Go Potassium Channels / genetics. GATA2 Transcription Factor / genetics. Mice. Mice, Transgenic. MicroRNAs / genetics. Moloney murine leukemia virus / genetics. Mutagenesis, Insertional. NIH 3T3 Cells. Neoplasm Proteins / genetics. Oncogene Proteins / genetics

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 1988 Sep 5;203(1):131-9 [3054118.001]
  • [Cites] Leukemia. 2005 Apr;19(4):636-43 [15744344.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1511-9 [7731705.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3713-8 [7780155.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5434-43 [7565694.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):348-53 [10610183.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):239-45 [10873593.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):224-34 [11113197.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):350-61 [11157742.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] Blood. 2005 Jul 1;106(1):287-95 [15755899.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7656-72 [16299527.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4269-77 [16105979.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6628-37 [16818636.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 13;349(1):59-68 [16934749.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1460-71 [17038527.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):417-20 [12124171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11293-8 [12151601.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):160-5 [12185367.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):281-96 [12566412.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):699-709 [12569362.001]
  • [Cites] J Virol. 2003 Apr;77(8):4965-71 [12663802.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4529-38 [12543865.001]
  • [Cites] Science. 2003 Jun 13;300(5626):1749-51 [12805549.001]
  • [Cites] Cell. 2003 Oct 17;115(2):135-8 [14567911.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D523-7 [14681473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4924-9 [15044690.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11334-7 [15273287.001]
  • [Cites] PLoS Biol. 2004 Aug;2(8):E234 [15314653.001]
  • [Cites] Trends Mol Med. 2004 Oct;10(10):500-7 [15464450.001]
  • [Cites] Virology. 1970 Dec;42(4):1136-9 [4099080.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):154-8 [8563753.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4269-73 [9766650.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Blood. 2005 Jan 15;105(2):784-93 [15454493.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):444-7 [2320112.001]
  • (PMID = 17545593.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC010378-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ERG1 potassium channel; 0 / Ether-A-Go-Go Potassium Channels; 0 / GATA2 Transcription Factor; 0 / Gata2 protein, mouse; 0 / Homeodomain Proteins; 0 / Hoxd13 protein, mouse; 0 / MicroRNAs; 0 / Mn1 protein, mouse; 0 / Neoplasm Proteins; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; 0 / myeloid ecotropic viral integration site 1 protein; 0 / nuclear pore complex protein 98
  • [Other-IDs] NLM/ NIHMS25088; NLM/ PMC1950322
  •  go-up   go-down


75. Stanulla M, Schäffeler E, Arens S, Rathmann A, Schrauder A, Welte K, Eichelbaum M, Zanger UM, Schrappe M, Schwab M: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol; 2005 Jan;81(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia.
  • The probability of event-free survival of childhood acute lymphoblastic leukemia (ALL) approaches 80% or more with the use of modern multiagent chemotherapeutic regimens.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glutathione Transferase / genetics. Isoenzymes / genetics. P-Glycoprotein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] J Clin Invest. 1996 Jun 1;97(11):2517-24 [8647944.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Pharmacol Ther. 1990;48(3):357-69 [2084706.001]
  • [Cites] Pharmacogenetics. 1998 Feb;8(1):27-31 [9511178.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):397-402 [9299520.001]
  • [Cites] Blood. 1994 Jul 15;84(2):355-66 [8025264.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:161-83 [8725386.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2):279-88 [10648456.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1847-54 [12089380.001]
  • [Cites] N Engl J Med. 2003 Apr 10;348(15):1442-8 [12686700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 [10716719.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):641-4 [9111193.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Aug;16(4):293-303 [2234311.001]
  • [Cites] Eur J Haematol. 2004 May;72(5):314-21 [15059065.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):83-105 [12535575.001]
  • [Cites] Joint Bone Spine. 2000 Jan;67(1):30-9 [10773966.001]
  • [Cites] Ann Hum Genet. 1989 Jul;53(Pt 3):205-13 [2596826.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Pharmacogenetics. 2001 Jun;11(4):293-8 [11434506.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Pharmacogenetics. 2000 Nov;10(8):715-26 [11186134.001]
  • [Cites] Eur J Biochem. 1994 Sep 15;224(3):893-9 [7925413.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:285-307 [12359865.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 15717687.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / P-Glycoprotein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


76. Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz OJ, Oscier D: ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica; 2005 Aug;90(8):1078-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia.
  • BACKGROUND AND OBJECTIVES: ZAP-70 expression is a recognized prognostic marker in chronic lymphocytic leukemia (CLL).
  • DESIGN AND METHODS: Patients with CLL (n=87), acute lymphoblastic leukemia (n=13), mantle cell leukemia (n=13) and splenic marginal zone lymphoma (n=14) of known immunoglobulin gene mutation (IgVH) status were studied.
  • [MeSH-major] DNA Methylation. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] 5' Untranslated Regions / genetics. Conserved Sequence. Dinucleoside Phosphates / genetics. Humans. Introns. Leukemia / genetics. Reference Values. Restriction Mapping

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Aug;90(8):1012 [16079094.001]
  • (PMID = 16079107.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Dinucleoside Phosphates; 2382-65-2 / cytidylyl-3'-5'-guanosine; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


77. Pound CM, Keene DL, Udjus K, Humphreys P, Johnston DL: Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2007 Mar;29(3):183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
  • A 7-year-old girl with an unusual reaction to induction chemotherapy for precursor B-cell acute lymphoblastic leukemia (ALL) is described.
  • The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
  • Neurologic status returned to baseline within 10 days of the acute event, and magnetic resonance angiography findings returned to normal 4 months later.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asparaginase / adverse effects. Brain Diseases / chemically induced. Burkitt Lymphoma / drug therapy. Cytarabine / adverse effects. Polyethylene Glycols / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vasospasm, Intracranial / chemically induced
  • [MeSH-minor] Acute Disease. Brain / pathology. Child. Female. Follow-Up Studies. Humans. Injections, Spinal. Magnetic Resonance Angiography / methods. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356399.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / pegaspargase; 04079A1RDZ / Cytarabine; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


78. Schnakenberg E, Mehles A, Cario G, Rehe K, Seidemann K, Schlegelberger B, Elsner HA, Welte KH, Schrappe M, Stanulla M: Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet; 2005 May 27;6:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population.
  • Two common polymorphisms (677C>T and 1298A>C) in the gene coding for MTHFR have been shown to reduce MTHFR enzyme activity and were associated with the susceptibility to different disorders, including vascular disease, neural tube defects and lymphoid malignancies.
  • Studies on the role of these polymorphisms in the susceptibility to acute lymphoblastic leukemia (ALL) led to discrepant results.
  • RESULTS: No significant associations between specific MTHFR variants or combinations of variants and risk of ALL were observed neither in the total patient group nor in analyses stratified by gender, age at diagnosis, DNA index, immunophenotype, or TEL/AML1 rearrangement.
  • [MeSH-major] Genetic Predisposition to Disease / epidemiology. Genetic Predisposition to Disease / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] Ann Hematol. 1999 Apr;78(4):157-62 [10348146.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] Blood. 2001 May 15;97(10):3205-9 [11342450.001]
  • [Cites] Atherosclerosis. 2001 Jun;156(2):409-15 [11395038.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):616-8 [11736945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14853-8 [11742092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5606-11 [11929966.001]
  • [Cites] Am J Hum Genet. 2002 Jul;71(1):193-7 [12058344.001]
  • [Cites] J Hum Genet. 2003;48(1):1-7 [12560871.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):571-82 [12672676.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):154-60 [12827651.001]
  • [Cites] Blood. 2004 Jan 1;103(1):252-7 [12958073.001]
  • [Cites] Haematologica. 2004 Feb;89(2):139-44 [15003888.001]
  • [Cites] Cancer Biol Ther. 2004 Jan;3(1):13-20 [14726677.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):787-94 [15159311.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] Circulation. 1997 Oct 21;96(8):2573-7 [9355896.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Mol Genet Metab. 1998 Jul;64(3):169-72 [9719624.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 15921520.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Other-IDs] NLM/ PMC1164414
  •  go-up   go-down


79. Linabery AM, Blair CK, Gamis AS, Olshan AF, Heerema NA, Ross JA: Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.
  • Children with Down syndrome, due to their heightened risk of leukemia and increased prevalence of congenital abnormalities, comprise a valuable population in which to study etiology.
  • A Children's Oncology Group study investigated the causes of childhood leukemia in children with Down syndrome diagnosed at ages 0 to 19 years during the period 1997-2002.
  • Telephone interviews were completed with mothers of 158 cases [n=97 acute lymphoblastic leukemia (ALL) and n=61 acute myeloid leukemia (AML)] and 173 controls.
  • Odds ratios (OR) and 95% confidence intervals (95% CI) were computed via unconditional logistic regression to evaluate the association between congenital abnormalities and acute leukemia overall, and ALL and AML analyzed separately.
  • The results do not provide evidence for an association among the index children (OR(Combined), 0.74; 95% CI, 0.45-1.23; OR(ALL), 0.67; 95% CI, 0.38-1.20; OR(AML),1.03; 95% CI, 0.49-2.16) or their siblings (OR(Combined), 1.23; 95% CI, 0.71-2.13; OR(ALL), 1.12; 95% CI, 0.60-2.09; OR(AML), 1.60; 95% CI, 0.66-3.86), suggesting congenital malformations do not confer additional risk of leukemia beyond the risk attributable to trisomy 21 in this population.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Birth Defects.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 1987;4(3):211-30 [2978961.001]
  • [Cites] Am J Hum Genet. 1990 Mar;46(3):478-85 [2309699.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):175-8 [11305722.001]
  • [Cites] Int J Epidemiol. 2001 Apr;30(2):350-2 [11369741.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2001 Dec 1;61(3):199-205 [11700189.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:5-7 [1532221.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):629-38 [8470664.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):357-63 [8347491.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Am J Hum Genet. 1997 Mar;60(3):474-85 [9042906.001]
  • [Cites] Am J Med Genet. 1998 Jan 6;75(1):22-7 [9450852.001]
  • [Cites] Am J Med Genet. 1998 Jun 5;77(5):431-8 [9632176.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1244-9 [9820188.001]
  • [Cites] J Pediatr. 1998 Nov;133(5):617-23 [9821417.001]
  • [Cites] Arch Dis Child. 1999 Jan;80(1):1-3 [10325750.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):8-12 [15390275.001]
  • [Cites] Cancer. 2005 May 1;103(9):1939-48 [15770693.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):405-10 [15952191.001]
  • [Cites] J Pediatr Health Care. 2006 Jan-Feb;20(1):47-54 [16399479.001]
  • [Cites] Nature. 2006 Jun 1;441(7093):595-600 [16554754.001]
  • [Cites] Pediatrics. 2006 Nov;118(5):e1499-508 [17030598.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):9-14 [17224656.001]
  • [Cites] JAMA. 2008 Jan 2;299(1):61-9 [18167407.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):500-6 [18296646.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1020-2 [6118480.001]
  • [Cites] Dev Med Child Neurol. 1982 Dec;24(6):817-29 [6218002.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • (PMID = 18829445.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016086-259036; United States / NIEHS NIH HHS / ES / P30 ES10126; United States / NCI NIH HHS / CA / T32 CA099936-01A1; United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / R01 CA075169-03; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / R01 CA075169; United States / NCI NIH HHS / CA / R01 CA75169; United States / NCI NIH HHS / CA / CA075169-03; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / P30 CA016086-259036; United States / NCI NIH HHS / CA / CA099936-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78459; NLM/ PMC2610427
  •  go-up   go-down


80. Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, Matherly LH, Schultz KR, Pflumio F, You MJ, Weng AP: Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood; 2010 Feb 11;115(6):1175-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
  • NOTCH1 is activated by mutation in more than 50% of human T-cell acute lymphoblastic leukemias (T-ALLs) and inhibition of Notch signaling causes cell-cycle/growth arrest, providing rationale for NOTCH1 as a therapeutic target.
  • It was recently observed among human T-ALL cell lines that PTEN loss correlated with resistance to Notch inhibition, raising concern that patients with PTEN-negative disease may fail Notch inhibitor therapy.
  • As these studies were limited to established cell lines, we addressed this issue using a genetically defined mouse retroviral transduction/bone marrow transplantation model and observed primary murine leukemias to remain dependent on NOTCH1 signaling despite Pten loss, with or without additional deletion of p16(Ink4a)/p19(Arf).
  • We also examined 13 primary human T-ALL samples obtained at diagnosis and found no correlation between PTEN status and resistance to Notch inhibition.
  • Furthermore, we noted in the mouse model that Pten loss accelerated disease onset and produced multiclonal tumors, suggesting NOTCH1 activation and Pten loss may collaborate in leukemia induction.
  • Thus, in contrast to previous findings with established cell lines, these results indicate PTEN loss does not relieve primary T-ALL cells of their "addiction" to Notch signaling.

  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2008 May 8;453(7192):228-32 [18418377.001]
  • [Cites] Curr Protoc Immunol. 2007 Aug;Chapter 8:Unit 8.17 [18432997.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3181-94 [18677410.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5497-510 [18794884.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3762-74 [18830414.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1730-40 [18984862.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6172-81 [19246562.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1063-6 [10871756.001]
  • [Cites] Br J Pharmacol. 2009 Nov;158(5):1183-95 [19775282.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4508-13 [11917122.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1784-9 [12411302.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1995 Feb 1;85(3):854 [7833489.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1765-9 [10208437.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6261-71 [16880534.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3579-87 [17213287.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5463-72 [17317856.001]
  • [Cites] Nat Med. 2007 Jun;13(6):736-41 [17515895.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] PLoS One. 2007;2(11):e1237 [18043744.001]
  • [Cites] Curr Protoc Mol Biol. 2001 Nov;Chapter 15:Unit 15.3 [18265117.001]
  • [Cites] Annu Rev Pathol. 2008;3:587-613 [18039126.001]
  • [Cites] Haematologica. 2008 Apr;93(4):533-42 [18322257.001]
  • [Cites] Nature. 2008 May 22;453(7194):529-33 [18463637.001]
  • (PMID = 20008304.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K22 CA112538; United States / NCI NIH HHS / CA / R01 CA076641; United States / NCI NIH HHS / CA / T32 CA009531; United States / NCI NIH HHS / CA / CA76641
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Enzyme Inhibitors; 0 / Il2rg protein, mouse; 0 / Interleukin Receptor Common gamma Subunit; 0 / RNA, Messenger; 0 / Receptor, Notch1; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC2826229
  •  go-up   go-down


81. Katzilakis N, Paraskakis E, Mantadakis E, Stiakaki E, Kalmanti M: Bronchial asthma and acute lymphoblastic leukemia in childhood. Pediatr Pulmonol; 2008 Feb;43(2):206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchial asthma and acute lymphoblastic leukemia in childhood.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Asthma / drug therapy. Asthma / prevention & control. Immunosuppressive Agents / administration & dosage. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / adverse effects. Drug Administration Schedule. Drug Therapy, Combination. Humans


82. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, Tedeschi A, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp MG, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R: A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood; 2005 May 1;105(9):3434-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.
  • The Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) 0496 protocol, through the central handling of bone marrow samples at presentation, allowed us to combine cytogenetic and molecular information on a large series of adults with acute lymphoblastic leukemia (ALL) treated homogeneously, enabling us to define as broadly as possible their genetic profile and to determine the impact on outcome of the cytogenetic-molecular signature.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


83. Shiozawa Y, Sakaguchi S, Sakakibara O, Yagishita K, Saito M, Yamashiro Y: Urolithiasis in an acute lymphoblastic leukemia child during induction chemotherapy. Pediatr Hematol Oncol; 2008 Jun;25(4):359-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urolithiasis in an acute lymphoblastic leukemia child during induction chemotherapy.
  • An 11-year-old acute lymphoblastic leukemia patient suddenly developed severe abdominal flank pain and hematuria caused by renal stone during induction chemotherapy.
  • Although urolithiasis is extremely rare in childhood acute lymphoblastic leukemia, it should be considered in patients who complain of abdominal flank pain or back pain during chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Urolithiasis / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18484482.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Oeffinger KC: Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):462-7; discussion 468
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?
  • Through a variety of different mechanisms, it appears that survivors of childhood acute lymphoblastic leukemia have an increased prevalence of several cardiovascular risk factors and thus are at increased risk for developing cardiovascular disease.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064658.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100474-04; United States / NCI NIH HHS / CA / R01 CA100474; United States / NCI NIH HHS / CA / R01 CA100474-04; United States / NCI NIH HHS / CA / R01-CA-100474
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


86. Jin FY, Zou DH, Wang GR, Xu Y, Feng SZ, Zhao YZ, Han MZ, Yan WW, Qiu LG: [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Zhonghua Xue Ye Xue Za Zhi; 2005 Nov;26(11):645-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
  • OBJECTIVE: To evaluate the effectiveness of chemotherapy (CT) and autologous hematopoietic stem cell transplantation (ASCT) as post-remission treatment for adult acute lymphoblastic leukemia (AL) patients.
  • The rates of leukemia free survival (LFS), overall survival (OS) and relapse were compared between the two groups. RESULTS:.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620547.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


87. Pereira Pinto L, de Souza LB, Gordón-Núñez MA, Soares RC, de Brito Costa EM, de Aquino AR, Fernandes MZ: Prevention of oral lesions in children with acute lymphoblastic leukemia. Int J Pediatr Otorhinolaryngol; 2006 Nov;70(11):1847-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of oral lesions in children with acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children and is responsible for severe stomatologic complications.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Chlorhexidine / analogs & derivatives. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Stomatitis / prevention & control

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914211.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antimetabolites, Antineoplastic; MOR84MUD8E / chlorhexidine gluconate; R4KO0DY52L / Chlorhexidine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


88. Wu YJ, Li JY, Zhu MQ, Song JH, Zheng WJ: [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jul;27(7):449-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens].
  • OBJECTIVE: To explore the diagnostic value of intracellular antibody combination in acute leukemia (AL) expressing cross-lineage cell-surface antigens.
  • RESULTS: Fifty-four of 269 previously untreated adult AL patients who expressed only one kind of intracellular antigen were diagnosed as cross-lineage AL, the percentage of cross-lineage AL in T cell acute lymphoblastic leukemia (T-ALL), B-ALL and acute myeloid leukemia (AML) was 28.6%, 43.6% and 13.4%, respectively.
  • Six (2.3%) patients expressed two-lineage intracellular antigens were diagnosed as biphenotypic AL: 2 of T/B type and 4 B/M (B/myeloid) type.
  • [MeSH-major] Antibodies, Monoclonal. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147246.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / Antigens, CD79; 0 / Antigens, Surface; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


89. Uckun FM, Dibirdik I, Qazi S, Yiv S: Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. Arzneimittelforschung; 2010;60(4):210-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Notably, WHI-P131-NP was capable of causing apoptotic death in primary leukemia cells from chemotherapy-resistant acute lymphoblastic leukemia (ALL) as well as chronic lymphocytic leukemia (CLL) patients.
  • These experimental results demonstrate that the nanotechnology-enabled delivery of WHI-P131 shows therapeutic potential against leukemias with constitutive activation of the JAK3-STAT3/STAT5 molecular target.
  • [MeSH-major] Antineoplastic Agents. Janus Kinase 3 / antagonists & inhibitors. Leukemia, B-Cell / drug therapy. Leukemia, Biphenotypic, Acute / drug therapy. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / pharmacology. Quinazolines / administration & dosage. Quinazolines / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Calibration. Cell Lineage. Chemistry, Pharmaceutical. Chromatography, High Pressure Liquid. Female. Humans. Liposomes. Mice. Mice, SCID. Nanoparticles. Osmolar Concentration. Particle Size

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arzneimittelforschung. 2010;60(5):286
  • (PMID = 20486472.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / WHI P131; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


90. Harrison TM, McKnight CA, Sikarskie JG, Kitchell BE, Garner MM, Raymond JT, Fitzgerald SD, Valli VE, Agnew D, Kiupel M: Malignant lymphoma in african lions (panthera leo). Vet Pathol; 2010 Sep;47(5):952-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemically, 10 of the 11 lions had T-cell lymphomas (CD3(+), CD79a(-)), and 1 lion was diagnosed with a B-cell lymphoma (CD3(-), CD79a(+)).
  • The spleen appeared to be the primary site of neoplastic growth in all T-cell lymphomas, with involvement of the liver (6/11) and regional lymph nodes (5/11) also commonly observed.
  • The B-cell lymphoma affected the peripheral lymph nodes, liver, and spleen.
  • According to the current veterinary and human World Health Organization classification of hematopoietic neoplasms, T-cell lymphoma subtypes included peripheral T-cell lymphoma (4/11), precursor (acute) T-cell lymphoblastic lymphoma/leukemia (2/11), chronic T-cell lymphocytic lymphoma/leukemia (3/11), and T-zone lymphoma (1/11).
  • The single B-cell lymphoma subtype was consistent with diffuse large B-cell lymphoma.
  • Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) testing by immunohistochemistry on sections of malignant lymphoma was negative for all 11 lions.
  • In contrast to domestic and exotic cats, in which B-cell lymphomas are more common than T-cell lymphomas, African lions in this study had malignant lymphomas that were primarily of T-cell origin.
  • [MeSH-major] Lions. Lymphoma / veterinary. Lymphoma, B-Cell / veterinary. Lymphoma, T-Cell / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610770.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Nyari TA, Kajtár P, Parker L: Seasonality of birth and acute lymphoblastic leukemia. J Perinat Med; 2006;34(6):507-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonality of birth and acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Seasons

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140306.001).
  • [ISSN] 0300-5577
  • [Journal-full-title] Journal of perinatal medicine
  • [ISO-abbreviation] J Perinat Med
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Germany
  •  go-up   go-down


92. Ohashi H, Kato C, Fukami S, Saito H, Hamaguchi M: Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases. Am J Hematol; 2005 Jun;79(2):142-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases.
  • We studied two cases with leukemia that relapsed in the central nervous system (CNS) after allogeneic stem cell transplantation.
  • One patient underwent peripheral blood stem cell transplantation (SCT) from a related, yet haplotype-mismatched, donor for chronic myelomonocytic leukemia.
  • In the other patient, with acute lymphoblastic leukemia, systemic relapse occurred when he was still on immunosuppression 6 months after SCT from an unrelated donor.
  • In both patients, the BM cells and all the fractions of the PB cells proved donor-type chimeras.
  • These results seem to suggest that the graft-versus-leukemia effects might not be as effective in the CNS as in the BM, even when complete T-lymphoid chimerism is achieved.
  • [MeSH-major] Bone Marrow / pathology. Central Nervous System Neoplasms / therapy. Leukemia / therapy. Neoplasm Recurrence, Local. Peripheral Blood Stem Cell Transplantation. Tissue Donors. Transplantation Chimera
  • [MeSH-minor] Adult. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelomonocytic, Chronic / pathology. Leukemia, Myelomonocytic, Chronic / therapy. Male. Middle Aged. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929112.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. De A, Menell JS: Isolated renal relapse in acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Mar;32(2):150-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated renal relapse in acute lymphoblastic leukemia.
  • Current therapy for acute lymphoblastic leukemia have resulted in cure rates over 80%.
  • We report the unusual case of a young man who presented with an isolated kidney relapse after maintaining remission from acute lymphoblastic leukemia for over 6 years.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048689.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Pui CH: Acute lymphoblastic leukemia: introduction. Semin Hematol; 2009 Jan;46(1):1-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia: introduction.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):47-58 [18598943.001]
  • [Cites] N Engl J Med. 2008 Aug 14;359(7):722-34 [18703475.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):481-9 [18710378.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):739-40 [17429386.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]
  • (PMID = 19100362.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Introductory Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS89425; NLM/ PMC2638983
  •  go-up   go-down


95. Melchers F: Starting at the end. Eur J Immunol; 2007 Nov;37 Suppl 1:S125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After more than 40 years in immunology, I have moved "backwards" over mature B cells, immature B cells, precursor B cells and lymphocyte progenitors to pluripotent hematopoietic stem cells.
  • Initially it was an intellectual exercise to trace the unknown progenitor of known B-lineage cells; now it has become an experimental approach - to de- and re-differentiate B-lineage cells to earlier differentiation stages and to other lineages of hematopoietic cells.
  • [MeSH-major] Allergy and Immunology / history. B-Lymphocytes / cytology. Cell Differentiation / immunology. Hematopoietic Stem Cells / cytology. Precursor Cells, B-Lymphoid / cytology
  • [MeSH-minor] Animals. Antibodies / immunology. Cell Lineage / immunology. History, 20th Century. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972356.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies
  • [Personal-name-as-subject] Melchers F
  •  go-up   go-down


96. Bohne A, Schlee C, Mossner M, Thibaut J, Heesch S, Thiel E, Hofmann WK, Baldus CD: Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. Leuk Res; 2009 Jun;33(6):817-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia.
  • Expression of ERG is of prognostic significance in acute myeloid leukemia (AML) and T-lymphoblastic leukemia (T-ALL) pointing to its role in leukemogenesis.
  • To unravel its transcriptional regulation we analyzed the expression of ERG specific isoforms.
  • Treatment of the T-lymphoblastic cell line BE13 with decitabine led to re-expression of ERG2 and pyrosequencing showed concordant DNA hypomethylation, thus confirming a methylation regulated expression of ERG2.
  • Moreover, the identification of a new ERG isoform (ERG3Deltaex12) suggests the association with different interaction partners and adds to the complexity of downstream pathways mediated by the expression of specific ERG transcripts in acute leukemia.
  • [MeSH-major] Epigenesis, Genetic. Oncogene Proteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein Isoforms / genetics. Trans-Activators / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108891.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / ERG protein, human; 0 / Oncogene Proteins; 0 / Protein Isoforms; 0 / Trans-Activators; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


97. Busse A, Gökbuget N, Siehl JM, Hoelzer D, Schwartz S, Rietz A, Thiel E, Keilholz U: Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol; 2009 Dec;88(12):1199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome.
  • Wilms' tumor gene 1 (WT1) is gaining increasing attention as a therapeutic target molecule due to its common expression in acute leukemias and its involvement in cell proliferation.
  • Here, we reported on WT1 messenger RNA expression levels at diagnosis in a series of 238 adult acute lymphoblastic leukemia (ALL) samples of various subtypes and clinical outcome.
  • Compared to a cohort of acute myeloid leukemia patients, the median WT1 expression level in ALL was significantly lower with large variations among different ALL subgroups.
  • Specifically, WT1 expression levels were low in mature B-ALL and highest in ALL cases with co-expression of myeloid markers, making it a useful therapeutic target molecule in adult ALL with the exception of mature B-ALL.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Genes, Wilms Tumor. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. WT1 Proteins

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Wilms' tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404640.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Messenger; 0 / WT1 Proteins
  •  go-up   go-down


98. Sim JP, Kho BC, Liu HS, Yung R, Chan JC: Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J; 2005 Apr;11(2):120-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin.
  • We report a case of Candida tropicalis arthritis of the knee that occurred in a patient with acute lymphoblastic leukaemia during the recovery phase of post-chemotherapy neutropenia.
  • The arthritis resolved after 7 weeks of combination therapy with caspofungin, a new echinocandin class of antifungal agent that acts primarily on the cell wall.

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815067.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


99. Aytaç S, Yildirim I, Ceyhan M, Cetin M, Tuncer M, Kara A, Cengiz AB, Seçmeer G, Yetgin S: Risks and outcome of fungal infection in neutropenic children with hematologic diseases. Turk J Pediatr; 2010 Mar-Apr;52(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this retrospective study, we report the results of antifungal treatments (AFTs) in febrile neutropenic episodes in patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA) in our center.
  • [MeSH-major] Anemia, Aplastic / complications. Antifungal Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Mycoses / drug therapy. Neutropenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560245.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  •  go-up   go-down


100. Seo-Mayer P, Kenney B, McNamara J, Stein J, Moeckel GW: Hematuria and decreased kidney function as initial signs of acute B-cell lymphoblastic leukemia. Am J Kidney Dis; 2010 Nov;56(5):1001-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematuria and decreased kidney function as initial signs of acute B-cell lymphoblastic leukemia.
  • We report the case of a 14-year-old boy who presented with hematuria and decreased kidney function as initial manifestations of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Hematuria / etiology. Kidney / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Renal Insufficiency / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Biopsy. Follow-Up Studies. Glomerular Filtration Rate. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20599308.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement